Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Last verified 25 Sep 2026 · Editorial standards

At a glance

Tislelizumab is named as an intervention in 566 current clinical trials in our China, USA, UK, Ireland and India registers. 360 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Sun Yat-sen University (58). The most-studied condition is Nasopharyngeal Carcinoma.

Trials by status

Recruiting36064%
Not yet open12522%
Active, closed7714%
By invitation41%

Trials by phase

Phase 233259%
Phase 38816%
Phase 1/26011%
Phase 1326%
Not applicable183%
Phase 2/3173%
Observational92%
Phase 461%
Phase EARLY_PHASE141%

Clinical trials of Tislelizumab

566 trials

Study	Phase	Status	Lead sponsor	Registers
Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of IPM514 in Patients with Esophageal Squamous Cell Carcinoma NCT06690476 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase EARLY_PHASE1	Recruiting	Peking University	China
Inhaled mRNA Tumor-associated Antigen Dry Powder Vaccine in Advanced Lung Cancer and Lung Metastasis of Solid Tumors. NCT06928922 · ClinicalTrials.gov ↗ · Advanced Lung Cancer, Lung Metastasis	Phase EARLY_PHASE1	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
An Exploratory Study of Personalized Cancer Vaccine in Adjuvant Therapy of Solid Tumors NCT07680582 · ClinicalTrials.gov ↗ · Solid Tumor	Phase EARLY_PHASE1	Recruiting	Ruijin Hospital	China
A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer NCT06457503 · ClinicalTrials.gov ↗ · Nasopharyngeal Cancer Recurrent	Phase 4	Recruiting	Coherus Oncology, Inc.	USA
Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II) NCT07320105 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 4	Recruiting	Fujian Cancer Hospital	China
Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC NCT04342910 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 3	Recruiting	Jiangsu HengRui Medicine Co., Ltd.	China
Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma NCT04453813 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma, Chemotherapy, Radiotherapy	Phase 3	Recruiting	Sun Yat-sen University	China
Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma NCT04453826 · ClinicalTrials.gov ↗ · Nasopharyngeal Cancer, Chemotherapy, Radiotherapy	Phase 3	Recruiting	Sun Yat-sen University	China
Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma NCT04778956 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma, PD-1, Surgery	Phase 3	Recruiting	Sun Yat-sen University	China
Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma NCT04944914 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 3	Recruiting	Sun Yat-sen University	China
PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer NCT05236972 · ClinicalTrials.gov ↗ · Colorectal Carcinoma	Phase 3	Recruiting	Sun Yat-sen University	China
A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma NCT05302284 · ClinicalTrials.gov ↗ · Urothelial Carcinoma, HER2-expressing	Phase 3	Recruiting	RemeGen Co., Ltd.	China
Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial NCT05340491 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 3	Recruiting	Sun Yat-sen University	China
Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study NCT05342194 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma	Phase 3	Recruiting	Shanghai Junshi Bioscience Co., Ltd.	China
Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma NCT05342792 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 3	Recruiting	Sun Yat-sen University	China
PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101) NCT05357846 · ClinicalTrials.gov ↗ · Squamous Cell Esophageal Carcinoma, Esophageal Cancer, Oesophageal Cancer	Phase 3	Recruiting	Sun Yat-sen University	China
Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE Ⅱ） NCT05429463 · ClinicalTrials.gov ↗ · Squamous Cell Non-small Cell Lung Cancer	Phase 3	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma NCT05495152 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 3	Recruiting	Henan Cancer Hospital	China
Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma NCT05613478 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Immunotherapy, Preoperative	Phase 3	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC. NCT05760378 · ClinicalTrials.gov ↗ · Triple-Negative Breast Cancer	Phase 3	Recruiting	Fudan University	China
Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy NCT05772208 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 3	Recruiting	Fudan University	China
Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma NCT05789043 · ClinicalTrials.gov ↗ · Acral Melanoma	Phase 3	Recruiting	Peking University Cancer Hospital & Institute	China
Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma NCT05798793 · ClinicalTrials.gov ↗ · Oral Squamous Cell Carcinoma	Phase 3	Recruiting	Hospital of Stomatology, Wuhan University	China
Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC NCT05854849 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 3	Recruiting	Sun Yat-sen University	China
A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma NCT05919030 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 3	Recruiting	Renmin Hospital of Wuhan University	China
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) NCT06095583 · ClinicalTrials.gov ↗ · Limited-stage Small Cell Lung Cancer (LS-SCLC)	Phase 3	Recruiting	Shanghai Junshi Bioscience Co., Ltd.	China
A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL) NCT06170489 · ClinicalTrials.gov ↗ · Hodgkin Lymphoma	Phase 3	Recruiting	Shanghai Junshi Bioscience Co., Ltd.	China
Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC NCT06177301 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 3	Recruiting	Fudan University	China
FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial NCT06201065 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 3	Recruiting	Sun Yat-sen University	China
Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis. NCT06383780 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 3	Recruiting	XIANG YANQUN	China
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation NCT06416410 · ClinicalTrials.gov ↗ · Advanced Non-squamous Non-small-cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer	Phase 3	Recruiting	Allist Pharmaceuticals, Inc.	China
Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial NCT06438627 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 3	Recruiting	XIANG YANQUN	China
Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer NCT06441110 · ClinicalTrials.gov ↗ · Urinary Bladder Neoplasms, BCG Vaccine, Immunotherapy, Active	Phase 3	Recruiting	Fujian Medical University Union Hospital	China
A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients NCT06497985 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 3	Recruiting	Chipscreen Biosciences, Ltd.	China
Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer NCT06520683 · ClinicalTrials.gov ↗ · Colorectal Cancer, Microsatellite Instability High	Phase 3	Recruiting	Sun Yat-sen University	China
Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer NCT06584032 · ClinicalTrials.gov ↗ · Advanced Endometrial Cancer	Phase 3	Recruiting	Hutchmed	China
9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer NCT06592326 · ClinicalTrials.gov ↗ · Urothelial Carcinoma	Phase 3	Recruiting	Mabwell (Shanghai) Bioscience Co., Ltd.	China
Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer: A Phase Ⅲ, Randomized, Multicenter, Prospective Study NCT06598527 · ClinicalTrials.gov ↗ · Lung Cancer (NSCLC)	Phase 3	Recruiting	Yang Hong	China
A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma NCT06618664 · ClinicalTrials.gov ↗ · Advanced Hepatocellular Carcinoma	Phase 3	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In NCT06745908 · ClinicalTrials.gov ↗ · NSCLC Stage IV	Phase 3	Recruiting	ImmunityBio, Inc.	UK, USA
Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma NCT06793917 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 3	Recruiting	Fujian Cancer Hospital	China
Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer NCT06889688 · ClinicalTrials.gov ↗ · Breast Cancer Stage IV, Triple -Negative Breast Cancer	Phase 3	Recruiting	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04) NCT06977893 · ClinicalTrials.gov ↗ · HR+/HER2- Breast Cancer	Phase 3	Recruiting	First Affiliated Hospital of Zhejiang University	China
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma NCT07043400 · ClinicalTrials.gov ↗ · Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma	Phase 3	Recruiting	BeOne Medicines	UK, USA, China
A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer NCT07111832 · ClinicalTrials.gov ↗ · PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer	Phase 3	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China
Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study NCT07132463 · ClinicalTrials.gov ↗ · Rectal Cancer	Phase 3	Recruiting	Fudan University	China
Adaptive Immunotherapy for Nasopharyngeal Carcinoma NCT07154069 · ClinicalTrials.gov ↗ · Nasopharyngeal Cancinoma (NPC)	Phase 3	Recruiting	Sun Yat-sen University	China
Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC NCT07177794 · ClinicalTrials.gov ↗ · Esophageal Cancer, Chemoradiotherapy	Phase 3	Recruiting	Sun Yat-sen University	China
Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC NCT07186621 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC), Radiotherapy, Adjuvant, Immune Checkpoint Inhibitor	Phase 3	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. NCT07315750 · ClinicalTrials.gov ↗ · Gastric Carcinoma	Phase 3	Recruiting	RemeGen Co., Ltd.	China
Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial NCT07340515 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma (NPC)	Phase 3	Recruiting	Man Hu	China
LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma NCT07362186 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic GC and GCJ Adenocarcinoma	Phase 3	Recruiting	LaNova Medicines Limited	China
Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma NCT07371611 · ClinicalTrials.gov ↗ · Locally Advanced Oral Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma (OSCC)	Phase 3	Recruiting	Qunxing Li,MD	China
Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma. NCT07385703 · ClinicalTrials.gov ↗ · Adenocarcinoma	Phase 3	Recruiting	Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.	China
RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC) NCT07416474 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 3	Recruiting	RemeGen Co., Ltd.	China
Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC NCT07459296 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma (NPC)	Phase 3	Recruiting	First Affiliated Hospital of Guangxi Medical University	China
A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence NCT07475026 · ClinicalTrials.gov ↗ · HCC - Hepatocellular Carcinoma	Phase 3	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07) NCT07502300 · ClinicalTrials.gov ↗ · Extensive-stage Small-cell Lung Cancer	Phase 3	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd.	China
Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy NCT07629817 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 3	Recruiting	Henan Cancer Hospital	China
Neoadjuvant RC48 Plus Gemcitabine in HER2-Expressing MIBC NCT07693959 · ClinicalTrials.gov ↗ · MIBC	Phase 3	Recruiting	Zhiquan Hu	China
Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal Carcinoma NCT07706985 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma (NPC)	Phase 3	Recruiting	Sun Yat-sen University	China
Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer NCT05699655 · ClinicalTrials.gov ↗ · Immunotherapy Gastrict Cancer	Phase 2/3	Recruiting	Fujian Cancer Hospital	China
Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC NCT06288373 · ClinicalTrials.gov ↗ · Cervical Cancer, Locally Advanced Cervical Cancer, Concurrent Chemoradiotherapy	Phase 2/3	Recruiting	Tongji Hospital	China
A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer NCT06312982 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Carcinoma	Phase 2/3	Recruiting	Beijing Friendship Hospital	China
Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment NCT06563245 · ClinicalTrials.gov ↗ · Classical Hodgkin Lymphoma, Child, Adolescent	Phase 2/3	Recruiting	Children's Cancer Group, China	China
Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC) NCT06796803 · ClinicalTrials.gov ↗ · Potentially Resectable Hepatocellular Carcinoma	Phase 2/3	Recruiting	Shanghai Zhongshan Hospital	China
A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02) NCT07554456 · Esophageal Squamous Cell Carcinoma	Phase 2/3	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd.	China
Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma NCT07643623 · ClinicalTrials.gov ↗ · Resectable Gastric/Gastroesophageal Junction Adenocarcinoma	Phase 2/3	Recruiting	Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.	China
SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer NCT07662395 · ClinicalTrials.gov ↗ · Double Blind	Phase 2/3	Recruiting	Sinocelltech Ltd.	China
Toripalimab（JS001） as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors NCT03810339 · ClinicalTrials.gov ↗ · Solid Tumor, Advanced Cancer	Phase 2	Recruiting	Sun Yat-sen University	China
Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer NCT03926338 · ClinicalTrials.gov ↗ · Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H)	Phase 2	Recruiting	Sun Yat-sen University	China
Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL) NCT04070040 · ClinicalTrials.gov ↗ · Primary Central Nervous System Lymphoma	Phase 2	Recruiting	Beijing Sanbo Brain Hospital	China
Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic Cholangiocarcinoma NCT04299581 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma	Phase 2	Recruiting	Fudan University	China
PLATFORM Study of Precision Medicine for Rare Tumors NCT04423185 · ClinicalTrials.gov ↗ · Rare Tumor	Phase 2	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC NCT04501523 · ClinicalTrials.gov ↗ · Triple-negative Breast Cancer	Phase 2	Recruiting	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma NCT04512534 · ClinicalTrials.gov ↗ · Peripheral T-cell Lymphoma	Phase 2	Recruiting	Fudan University	China
Toripalimab Combined With CAV/IE Regimen NCT04589741 · ClinicalTrials.gov ↗ · Soft Tissue Sarcoma	Phase 2	Recruiting	Sun Yat-sen University	China
Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC NCT04615143 · ClinicalTrials.gov ↗ · Recurrent Hepatocellular Carcinoma	Phase 2	Recruiting	Sun Yat-sen University	China
Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer NCT04728724 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Stage III	Phase 2	Recruiting	Shanghai Pulmonary Hospital, Shanghai, China	China
Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002) NCT04807140 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma	Phase 2	Recruiting	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma NCT04888429 · ClinicalTrials.gov ↗ · Sarcomatoid Carcinoma of Lung	Phase 2	Recruiting	Qian Chu	China
Toripalimab Plus FLOT in Locally Advanced Gastric Cancer NCT04891016 · ClinicalTrials.gov ↗ · Chemotherapy, Immune Checkpoint Inhibitor, Locally Advanced Gastric Carcinoma	Phase 2	Recruiting	Henan Cancer Hospital	China
Immune Checkpoint Inhibitor PD-1 Antibody Combined With Chemotherapy in the Perioperative Treatment of Locally Advanced Resectable Gastric or Gastroesophageal Junction Adenocarcinoma NCT04908566 · ClinicalTrials.gov ↗ · Locally Advanced Gastric Adenocarcinoma	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma NCT04954781 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma	Phase 2	Recruiting	Fudan University	China
Orelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System Lymphoma NCT04961515 · ClinicalTrials.gov ↗ · Primary Central Nervous System Hodgkin Lymphoma	Phase 2	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
Cryoablation Combined with Tislelizumab Plus Lenvatinib As Second-line or Later Therapy in Advanced Hepatocellular Carcinoma NCT05057845 · ClinicalTrials.gov ↗ · Advanced Hepatocellular Carcinoma	Phase 2	Recruiting	Fudan University	China
Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients NCT05069857 · ClinicalTrials.gov ↗ · Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1	Phase 2	Recruiting	Shanghai Jiao Tong University School of Medicine	China
Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002) NCT05098119 · ClinicalTrials.gov ↗ · Oral Cavity Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma	Phase 2	Recruiting	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia NCT05139095 · ClinicalTrials.gov ↗ · Gestational Trophoblastic Neoplasia	Phase 2	Recruiting	Peking Union Medical College Hospital	China
Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma NCT05147844 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 2	Recruiting	Xinqiao Hospital of Chongqing	China
Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE) NCT05165407 · ClinicalTrials.gov ↗ · Neuroendocrine Neoplasm	Phase 2	Recruiting	Peking University	China
Neoadjuvant Immunochemotherapy in Locally Advanced Esophagogastric Junction Adenocarcinoma NCT05170503 · ClinicalTrials.gov ↗ · Esophagogastric Junction Adenocarcinoma	Phase 2	Recruiting	Sun Yat-sen University	China
First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma NCT05188859 · ClinicalTrials.gov ↗ · Mesothelioma, Malignant, Mesothelioma, Malignant Pleural, Mesothelioma Malignant Advanced	Phase 2	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) NCT05447702 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer	Phase 2	Recruiting	West China Hospital	China
Neoadjuvant Chemoradiotherapy Plus Sintilimab for Intermediate/High Immunoscore Locally Advanced Rectal Cancer NCT05450029 · ClinicalTrials.gov ↗ · Rectal Cancer	Phase 2	Recruiting	Yanhong Deng	China
Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy NCT05468242 · ClinicalTrials.gov ↗ · Stage III Non-small Cell Lung Cancer	Phase 2	Recruiting	Sun Yat-sen University	China
Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer NCT05511623 · ClinicalTrials.gov ↗ · Cervical Cancer	Phase 2	Recruiting	First Affiliated Hospital of Guangxi Medical University	China
Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma NCT05512351 · ClinicalTrials.gov ↗ · Oligodendroglioma	Phase 2	Recruiting	Henan Provincial People's Hospital	China
Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma NCT05515315 · ClinicalTrials.gov ↗ · Immunotherapy Esophagus Cancer	Phase 2	Recruiting	Fuzhou General Hospital	China
Fluzoparib Combined With Camrelizumab for Neoadjuvant Treatment of Embryogenic BRCA Mutation HER2 Negative Breast Cancer: an Open, Single Arm, Multicenter Study NCT05576389 · ClinicalTrials.gov ↗ · Germline BRCA-mutated HER2-negative Breast Cancer	Phase 2	Recruiting	Peking University People's Hospital	China
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy NCT05582499 · ClinicalTrials.gov ↗ · Breast Neoplasm, Breast Cancer, Breast Tumors	Phase 2	Recruiting	Fudan University	China
Radiotherapy With Tislelizumab in Patients With Recurrent Head & Neck Cancer NCT05595590 · ClinicalTrials.gov ↗ · Head and Neck Cancer	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer. NCT05624099 · ClinicalTrials.gov ↗ · Esophageal Neoplasms, Esophageal Diseases, Digestive System Neoplasms	Phase 2	Recruiting	Fujian Cancer Hospital	China
The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer NCT05628038 · ClinicalTrials.gov ↗ · Recurrent Rectal Cancer	Phase 2	Recruiting	Fudan University	China
Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma NCT05687357 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastroesophageal-junction Cancer	Phase 2	Recruiting	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	China
Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma NCT05729646 · ClinicalTrials.gov ↗ · Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Mismatch Repair Deficiency	Phase 2	Recruiting	Yu jiren	China
Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation NCT05761470 · ClinicalTrials.gov ↗ · Her-2 Negative Breast Cancer, HRR Gene Mutation	Phase 2	Recruiting	Ying Lin	China
Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors NCT05768464 · ClinicalTrials.gov ↗ · Non-clear Renal Cell Carcinoma	Phase 2	Recruiting	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	China
Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients NCT05771181 · ClinicalTrials.gov ↗ · Colorectal Cancer, Microsatellite Stable Colorectal Carcinoma	Phase 2	Recruiting	Fudan University	China
The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer NCT05798845 · ClinicalTrials.gov ↗ · NSCLC	Phase 2	Recruiting	Shanghai Chest Hospital	China
Efficacy and Safety of Tislelizumab in Combination With Disitamab-vedotin as Neoadjuvant Therapy for HER2-positive High-risk Upper Tract Urothelial Carcinoma (UTUC) NCT05837806 · ClinicalTrials.gov ↗ · Neoadjuvant Immunotherapy	Phase 2	Recruiting	Tianjin Medical University Second Hospital	China
Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single-arm, Prospective, Phase II Trial NCT05862168 · ClinicalTrials.gov ↗ · Oral Squamous Cell Carcinoma	Phase 2	Recruiting	Weijia Fang, MD	China
A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study NCT05934331 · ClinicalTrials.gov ↗ · Malignant Neoplasms of Digestive Organs	Phase 2	Recruiting	LaNova Medicines Zhejiang Co., Ltd.	China
Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer NCT05963490 · ClinicalTrials.gov ↗ · Microsatellite Stable Metastatic Colorectal Cancer	Phase 2	Recruiting	Fudan University	China
Nodes-sparing Short-course Radiation Combined With CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer NCT05972655 · ClinicalTrials.gov ↗ · Low Rectal Cancer	Phase 2	Recruiting	Sir Run Run Shaw Hospital	China
Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma NCT06013618 · ClinicalTrials.gov ↗ · Neuroblastoma	Phase 2	Recruiting	Sun Yat-Sen University Cancer Center	China
Toripalimab Plus Actinomycin-D As Fist-Line Treatment for GTN with FIGO Score 7 NCT06020755 · ClinicalTrials.gov ↗ · Gestational Trophoblastic Neoplasia	Phase 2	Recruiting	Peking Union Medical College Hospital	China
Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial NCT06031285 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 2	Recruiting	Sun Yat-sen University	China
Cryoablation Combined with Tislelizumab Plus Lenvatinib in Previously Treated Solid Tumors (CASTLE-11) NCT06032845 · ClinicalTrials.gov ↗ · Solid Tumor, Adult	Phase 2	Recruiting	Fudan University	China
Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (PLOF) for Resectable Locally Advanced Gastric Cancer NCT06054906 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 2	Recruiting	Huashan Hospital	China
Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma NCT06056336 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy, Adjuvant Therapy	Phase 2	Recruiting	Guo Xufeng	China
Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer NCT06121505 · ClinicalTrials.gov ↗ · Lung Squamous Cell Carcinoma	Phase 2	Recruiting	Sichuan University	China
A Study of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 Mutations NCT06124963 · ClinicalTrials.gov ↗ · Gastric Type Adenocarcinoma (GAS) With STK11 Mutation	Phase 2	Recruiting	Shanghai Jiatan Pharmatech Co., Ltd	China
Immune Checkpoint Inhibitors Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC NCT06132698 · ClinicalTrials.gov ↗ · NSCLC Associated With Leptomeningeal Metastases	Phase 2	Recruiting	West China Hospital	China
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing NCT06145308 · ClinicalTrials.gov ↗ · Salivary Gland Carcinoma, Precision Therapy	Phase 2	Recruiting	Peking Union Medical College	China
Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma. NCT06155383 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma	Phase 2	Recruiting	RemeGen Co., Ltd.	China
Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore NCT06157996 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 2	Recruiting	Nanfang Hospital, Southern Medical University	China
Camrelizumab Combined With Chemotherapy and Radiotherapy Perioperative Treatment of Esophageal Gastric Junction Adenocarcinoma NCT06163729 · ClinicalTrials.gov ↗ · Gastroesophageal Junction Adenocarcinoma (Siewert II-III)	Phase 2	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC NCT06170710 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma	Phase 2	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer NCT06176885 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 2	Recruiting	yue junhan	China
DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer NCT06178159 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Recruiting	RemeGen Co., Ltd.	China
Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007) NCT06187597 · ClinicalTrials.gov ↗ · Locally Advanced Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	Sun Yat-sen University	China
A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC NCT06190639 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	Zhejiang Cancer Hospital	China
A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy NCT06208826 · ClinicalTrials.gov ↗ · Head and Neck Cancer	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
The Efficacy and Safety of Low-dose Radiotherapy Combined With Sintilimab and Temozolomide in Recurrent Glioblastoma NCT06220552 · ClinicalTrials.gov ↗ · Recurrent Glioblastoma	Phase 2	Recruiting	Fifth Affiliated Hospital, Sun Yat-Sen University	China
A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head and Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral Blood NCT06240689 · ClinicalTrials.gov ↗ · Locally Advanced Head and Neck Squamous Cell Carcinoma	Phase 2	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC NCT06241807 · ClinicalTrials.gov ↗ · IMMUNOTHERAPY, Neoadjuvant Therapy, Resectable Lung Non-Small Cell Carcinoma	Phase 2	Recruiting	Shandong Cancer Hospital and Institute	China
The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer NCT06254521 · ClinicalTrials.gov ↗ · Rectal Cancer, Rectal Cancer Stage II, Rectal Cancer Stage III	Phase 2	Recruiting	First Affiliated Hospital of Guangxi Medical University	China
A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy NCT06255223 · ClinicalTrials.gov ↗ · Renal Cell Carcinoma, Radiotherapy, Immune Checkpoint Inhibitor	Phase 2	Recruiting	Jinling Hospital, China	China
Neoadjuvant Immunochemotherapy in PD-L1-negative LACC NCT06288360 · ClinicalTrials.gov ↗ · Cervical Cancer, Locally Advanced Cervical Cancer, PD-L1 Negative	Phase 2	Recruiting	Tongji Hospital	China
Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer NCT06289062 · ClinicalTrials.gov ↗ · Cervical Cancer, Neoadjuvant Chemoimmunotherapy, Fertility Preservation	Phase 2	Recruiting	Tongji Hospital	China
Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402) NCT06313190 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 2	Recruiting	Sun Yat-sen University	China
Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma NCT06314334 · ClinicalTrials.gov ↗ · Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type	Phase 2	Recruiting	Fudan University	China
SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma NCT06323239 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 2	Recruiting	Sun Yat-sen University	China
Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM NCT06341595 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastric Cancer Metastatic to Regional Lymph Nodes	Phase 2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC NCT06360042 · ClinicalTrials.gov ↗ · Unresectable Hepatocellular Carcinoma	Phase 2	Recruiting	Peking University Cancer Hospital & Institute	China
A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma NCT06363825 · ClinicalTrials.gov ↗ · Advanced Hepatocellular Carcinoma	Phase 2	Recruiting	Fujian Medical University	China
Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO) NCT06387056 · ClinicalTrials.gov ↗ · Locally Advanced Prostate Cancer, Oligometastatic Prostate Cancer	Phase 2	Recruiting	The First Affiliated Hospital of Xiamen University	China
To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer NCT06389006 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Recruiting	RemeGen Co., Ltd.	China
Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma NCT06413342 · ClinicalTrials.gov ↗ · Esophageal Cancer, Chemoradiotherapy, Sintilimab	Phase 2	Recruiting	Zhejiang Cancer Hospital	China
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer NCT06413992 · ClinicalTrials.gov ↗ · Endometrial Carcinoma, TP53 Mutation, Recurrent or Metastatic	Phase 2	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model NCT06420440 · HCC	Phase 2	Recruiting	Chen Xiaoping	China
A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy. NCT06421298 · ClinicalTrials.gov ↗ · Lung Cancer	Phase 2	Recruiting	Jinghui Wang	China
A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs NCT06423170 · ClinicalTrials.gov ↗ · Unresectable Gallbladder Cancer	Phase 2	Recruiting	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer NCT06435260 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 2	Recruiting	Hebei Medical University Fourth Hospital	China
Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma NCT06446726 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	Sichuan University	China
Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer NCT06451211 · ClinicalTrials.gov ↗ · Stomach Neoplasms, Gastric Cancer, Linitis Plastica of Stomach	Phase 2	Recruiting	Sun Yat-sen University	China
Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE) NCT06455124 · ClinicalTrials.gov ↗ · Rectal Cancer	Phase 2	Recruiting	Fudan University	China
Short-course Radiotherapy Combined With CAPOX and PD-1 Antibody Versus Long-course Chemoradiotherapy Combined With CAPOX for Early Low-lying Rectal Cancer NCT06462053 · ClinicalTrials.gov ↗ · Early Low Rectal Cancer	Phase 2	Recruiting	Fudan University	China
A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma NCT06463834 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	Fujian Cancer Hospital	China
Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical Study NCT06538896 · ClinicalTrials.gov ↗ · Triple-negative Breast Cancer, Bone Metastases	Phase 2	Recruiting	Zhejiang Cancer Hospital	China
Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study NCT06547203 · ClinicalTrials.gov ↗ · Colorectal Cancer Metastatic	Phase 2	Recruiting	Sun Yat-sen University	China
A Single-arm, Phase II Exploratory Study of Sintilimab in Combination With Chemoradiotherapy in Elderly Patients With Locally Advanced Gastric Cancer NCT06555471 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma NCT06558227 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 2	Recruiting	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	China
Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer NCT06561308 · ClinicalTrials.gov ↗ · Endometrioid Endometrial Cancer	Phase 2	Recruiting	Women's Hospital School Of Medicine Zhejiang University	China
Sintilimab With P-GEMOX Versus the P-GEMOX in the Teatment of Advanced-stage Extranodal Natural Killer/T Cell Lymphoma NCT06583083 · ClinicalTrials.gov ↗ · Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type	Phase 2	Recruiting	Sun Yat-sen University	China
A Study on the Efficacy and Safety of Multi-mode Ablation Combined With Systemic Therapy in the Treatment of CRCLM NCT06590259 · ClinicalTrials.gov ↗ · Colorectal Cancer Liver Metastasis	Phase 2	Recruiting	Shanghai 6th People's Hospital	China
A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer NCT06623136 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 2	Recruiting	Elpiscience (Suzhou) Biopharma, Ltd.	China
All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi-cohort Phase II Trial NCT06636981 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer (TNBC)	Phase 2	Recruiting	Fudan University	China
Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer NCT06642545 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Recruiting	RemeGen Co., Ltd.	China
Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell Carcinoma NCT06646588 · Esophageal Neoplasms	Phase 2	Recruiting	Hebei Medical University Fourth Hospital	China
Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperative Recurrent High-risk Intrahepatic Cholangiocarcinoma NCT06664021 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma	Phase 2	Recruiting	Anhui Provincial Hospital	China
Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02) NCT06682195 · ClinicalTrials.gov ↗ · TNBC, Triple Negative Breast Cancer	Phase 2	Recruiting	First Affiliated Hospital of Zhejiang University	China
Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer NCT06685276 · ClinicalTrials.gov ↗ · Colorectal Cancer Metastatic	Phase 2	Recruiting	Dai, Guanghai	China
Combination of Toripalimab and JS004 Therapy for ccRCC NCT06690697 · ClinicalTrials.gov ↗ · Clear Cell Renal Cell Carcinoma	Phase 2	Recruiting	Fudan University	China
Different Cycles of Preoperative Neoadjuvant Sintilimab in Mismatch-repair Deficient/microsatellite Instability-high, Locally Advanced Colorectal Cancer NCT06698757 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 2	Recruiting	Yugui Lian	China
Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC. NCT06705127 · ClinicalTrials.gov ↗ · HR-positive,HER2-negative Breast Cancer	Phase 2	Recruiting	First Affiliated Hospital of Zhejiang University	China
A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS) NCT06709417 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma (ESCC)	Phase 2	Recruiting	Shanghai Chest Hospital	China
Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma NCT06718205 · ClinicalTrials.gov ↗ · Esophageal Cancer	Phase 2	Recruiting	The First Affiliated Hospital of Zhengzhou University	China
First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2) NCT06730373 · ClinicalTrials.gov ↗ · HER2-positive Gastric Cancer, Metastatic Gastric Cancer, Unresectable Gastric Carcinoma	Phase 2	Recruiting	Qilu Hospital of Shandong University	China
Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression NCT06749860 · ClinicalTrials.gov ↗ · Lung Cancer	Phase 2	Recruiting	Shanghai Pulmonary Hospital, Shanghai, China	China
An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting NCT06749886 · ClinicalTrials.gov ↗ · Lung Cancer	Phase 2	Recruiting	Shanghai Pulmonary Hospital, Shanghai, China	China
Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and GEJ NCT06761846 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma, Esophagogastric Junction Adenocarcinoma	Phase 2	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
A Study of RC48-ADC Combined With JS001 for Advanced Extramammary Paget Disease of the Scrotum NCT06791070 · ClinicalTrials.gov ↗ · Paget Disease, Extramammary, Scrotum Disease	Phase 2	Recruiting	Fujian Medical University Union Hospital	China
To Explore the Efficacy of Sintilimab Combined With Bevacizumab in Rectal Cancer NCT06808412 · ClinicalTrials.gov ↗ · Rcctal Cancer	Phase 2	Recruiting	xiaohua li	China
9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma NCT06823427 · ClinicalTrials.gov ↗ · Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent	Phase 2	Recruiting	Mabwell (Shanghai) Bioscience Co., Ltd.	China
"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer" NCT06829355 · ClinicalTrials.gov ↗ · MCRC	Phase 2	Recruiting	Beijing Friendship Hospital	China
Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Cancer NCT06841159 · ClinicalTrials.gov ↗ · Microsatellite Stable Metastatic Colorectal Cancer	Phase 2	Recruiting	Fudan University	China
A Phase II Study of Toripalimab Combined With Sequential Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma NCT06843889 · ClinicalTrials.gov ↗ · Locally Advanced Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	Nanfang Hospital, Southern Medical University	China
Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II Study NCT06848569 · ClinicalTrials.gov ↗ · Classical Hodgkin Lymphoma	Phase 2	Recruiting	Sun Yat-sen University	China
IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS) NCT06849986 · ClinicalTrials.gov ↗ · Soft Tissue Sarcomas, Angiosarcoma, Fibrosarcoma	Phase 2	Recruiting	Fudan University	China
GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma. NCT06851247 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 2	Recruiting	Sun Yat-sen University	China
Cryoablation Combined With Lenvatinib Plus Tislelizumab Compared With FOLFOX in Patients With Advanced Intrahepatic Cholangiocarcinoma (CASTLE-ZS-01) NCT06860477 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocellular Carcinoma	Phase 2	Recruiting	Fudan University	China
HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03) NCT06860490 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)	Phase 2	Recruiting	Fudan University	China
A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer NCT06869226 · ClinicalTrials.gov ↗ · Esophageal Cancer	Phase 2	Recruiting	Peking University Cancer Hospital & Institute	China
Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer NCT06903858 · ClinicalTrials.gov ↗ · Colorectal Cancer, Microsatellite Instability High, Mismatch Repair Deficiency	Phase 2	Recruiting	Sun Yat-sen University	China
Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCC NCT06904014 · ClinicalTrials.gov ↗ · HCC	Phase 2	Recruiting	Lei ZHAO	China
Probiotics in Advanced Urothelial Carcinoma NCT06904573 · ClinicalTrials.gov ↗ · Advanced Urothelial Carcinoma, Probiotics, Immunotherapy	Phase 2	Recruiting	Sun Yat-sen University	China
TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma NCT06912711 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 2	Recruiting	Sun Yat-sen University	China
Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer NCT06914440 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Recruiting	Xijing Hospital	China
Neoadjuvant High-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab and Chemotherapy for ER-Positive /HER2-Negative Breast Cancer NCT06964906 · ClinicalTrials.gov ↗ · ER+/HER2- Breast Cancer	Phase 2	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial NCT06965231 · ClinicalTrials.gov ↗ · Melanoma of Skin, Acral Melanoma, Stage II Melanoma	Phase 2	Recruiting	Fudan University	China
Cetuximab + Tislelizumab + Chemotherapy in the Treatment of Unresectable LA HNSCC NCT06978829 · ClinicalTrials.gov ↗ · LA HNSCC	Phase 2	Recruiting	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University	China
A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal Cancer NCT06979908 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 2	Recruiting	The First Hospital of Jilin University	China
Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma NCT07030140 · ClinicalTrials.gov ↗ · Cholangiocarcinoma, Hilar Cholangiocarcinoma, Bile Duct Cancer	Phase 2	Recruiting	Jinbo Yue	China
Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma NCT07039162 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma (ESCC), Locally Advanced Unresectable Esophageal Cancer	Phase 2	Recruiting	Ming-Yu Lien	China
Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Non-small Cell Lung Cancer With or Without Prior Neoadjuvant Therapy NCT07039656 · ClinicalTrials.gov ↗ · Stage IB-IIIB NSCLC, Stage IIB-III NSCLC	Phase 2	Recruiting	Wen-zhao ZHONG	China
Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab NCT07047586 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)	Phase 2	Recruiting	Fudan University	China
Tislelizumab Combined With Thoracic Radiotherapy as Neoadjuvant Therapy for Resectable NSCLC NCT07050056 · ClinicalTrials.gov ↗ · Resectable NSCLC	Phase 2	Recruiting	Northern Jiangsu People's Hospital	China
Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITL NCT07058103 · ClinicalTrials.gov ↗ · Angioimmunoblastic T-Cell Lymphoma Recurrent, Angioimmunoblastic T-Cell Lymphoma Refractory	Phase 2	Recruiting	The Affiliated Hospital of Xuzhou Medical University	China
Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer NCT07086456 · Surufatinib, Tislelizumab, Concurrent Chemoradiotherapy	Phase 2	Recruiting	Sun Yat-sen University	China
Induction Immunotherapy Combined With Chemotherapy Followed by Concurrent Chemoradiotherap and Immunotherapy for Cervical Cancer NCT07092696 · ClinicalTrials.gov ↗ · Cervical Cancer	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma NCT07099547 · ClinicalTrials.gov ↗ · Biliary Tract Carcinoma	Phase 2	Recruiting	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	China
Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Tislelizumab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally Advanced Rectal Adenocarcinoma With Low Rectal Involvement NCT07104604 · ClinicalTrials.gov ↗ · Rectal Cancer	Phase 2	Recruiting	Affiliated Cancer Hospital of Shantou University Medical College	China
Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial NCT07106034 · ClinicalTrials.gov ↗ · Advanced Colorectal Cancer	Phase 2	Recruiting	Shanghai Pudong Hospital	China
Perioperative Immunotherapy for Resectable Limited-Stage SCLC NCT07109401 · ClinicalTrials.gov ↗ · Perioperative Immunotherapy, Limited Stage Lung Small Cell Carcinoma, Resectable Small Cell Lung Cancer	Phase 2	Recruiting	Fudan University	China
Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung) NCT07120698 · ClinicalTrials.gov ↗ · NSCLC (Non-small Cell Lung Cancer), MRD, II-IIIB Stages	Phase 2	Recruiting	Guangdong Association of Clinical Trials	China
Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC NCT07126119 · ClinicalTrials.gov ↗ · Upper Tract Urothelial Carcinoma, Neoadjuvant Therapy, PD-1 Inhibitor	Phase 2	Recruiting	Tianjin Medical University Second Hospital	China
Tislelizumab Combined With Chemotherapy for Different Cycles of Neoadjuvant Therapy for Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck (NeoTempo) NCT07147426 · ClinicalTrials.gov ↗ · Head &Amp; Neck Squamous Cell Carcinoma	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC NCT07157969 · ClinicalTrials.gov ↗ · HCC - Hepatocellular Carcinoma	Phase 2	Recruiting	Peking Union Medical College Hospital	China
Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial NCT07167160 · ClinicalTrials.gov ↗ · Cervical Cancer, Immunochemotherapy	Phase 2	Recruiting	Women's Hospital School Of Medicine Zhejiang University	China
Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of New Diagnosed AITL NCT07168317 · ClinicalTrials.gov ↗ · New Diagnosed Angioimmunoblastic T-Cell Lymphoma	Phase 2	Recruiting	The Affiliated Hospital of Xuzhou Medical University	China
Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma NCT07179900 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 2	Recruiting	Hebei Medical University Fourth Hospital	China
Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric Cancer NCT07194005 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 2	Recruiting	Fudan University	China
Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer NCT07233252 · ClinicalTrials.gov ↗ · Renal Pelvic Carcinoma, Tislelizumab, PD-1 Inhibitor	Phase 2	Recruiting	Tianjin Medical University Second Hospital	China
Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI Treatment NCT07238881 · ClinicalTrials.gov ↗ · Hepatocellulcar Carcinoma	Phase 2	Recruiting	Sun Yat-sen University	China
Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC NCT07296705 · ClinicalTrials.gov ↗ · Muscle Invasive Bladder Cancer (MIBC)	Phase 2	Recruiting	Fujian Medical University Union Hospital	China
A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer NCT07309276 · ClinicalTrials.gov ↗ · Advanced Lung Cancer	Phase 2	Recruiting	Shanghai Junshi Bioscience Co., Ltd.	China
Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC NCT07309952 · ClinicalTrials.gov ↗ · Locally Advanced Non-Small Cell Lung Cancer, Stage IIIb Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer	Phase 2	Recruiting	Yang Hong	China
9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer NCT07314723 · ClinicalTrials.gov ↗ · Urothelial Carcinoma	Phase 2	Recruiting	Mabwell (Shanghai) Bioscience Co., Ltd.	China
Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer NCT07320586 · ClinicalTrials.gov ↗ · Gastric Cancer, Second-line Therapy	Phase 2	Recruiting	Shandong Tumor Hospital	China
Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma NCT07324824 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Neoadjuvant Therapy, Sintilimab	Phase 2	Recruiting	Sun Yat-sen University	China
A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma NCT07328009 · ClinicalTrials.gov ↗ · Hepato Cellular Carcinoma (HCC)	Phase 2	Recruiting	Fudan University	China
TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy NCT07330037 · ClinicalTrials.gov ↗ · NSCLC	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)] NCT07331155 · ClinicalTrials.gov ↗ · Advanced Solid Tumour	Phase 2	Recruiting	Nanjing Leads Biolabs Co.,Ltd	China
Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2) NCT07331883 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)	Phase 2	Recruiting	Ruijin Hospital	China
A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC NCT07334483 · ClinicalTrials.gov ↗ · HCC	Phase 2	Recruiting	GrandPharma (China) Co., Ltd.	China
Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer NCT07353723 · ClinicalTrials.gov ↗ · Head & Neck Cancer	Phase 2	Recruiting	Tang-Du Hospital	China
Induction Chemotherapy Combined With Tislelizumab for Locally Advanced Squamous Cell Carcinoma of the External Auditory Canal NCT07370337 · ClinicalTrials.gov ↗ · Squamous Cell Carcinoma of External Auditory Canal, Locally Advanced Tumor	Phase 2	Recruiting	Eye & ENT Hospital of Fudan University	China
FMD and Neoadjuvant Chemo-immunotherapy in TNBC NCT07378306 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Recruiting	Sun Yat-sen University	China
PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL NCT07380984 · ClinicalTrials.gov ↗ · Natural Killer/T-cell Lymphoma	Phase 2	Recruiting	Ruijin Hospital	China
A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04] NCT07390383 · ClinicalTrials.gov ↗ · Advanced Solid Tumour	Phase 2	Recruiting	Nanjing Leads Biolabs Co.,Ltd	China
Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer. NCT07394387 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer (TNBC)	Phase 2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery NCT07400302 · ClinicalTrials.gov ↗ · Mucosal Melanoma, PD-L1 Positive	Phase 2	Recruiting	The First Hospital of Jilin University	China
Becotatug Vedotin ± Anti-PD-1 in Pretreated Advanced ESCC NCT07403136 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	Fudan University	China
Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer NCT07410975 · ClinicalTrials.gov ↗ · NSCLC Stage II, NSCLC Stage III	Phase 2	Recruiting	Shanghai Pulmonary Hospital, Shanghai, China	China
Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma NCT07413354 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)	Phase 2	Recruiting	Tongji Hospital	China
Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of Extensive Stage Small Cell Lung Cancer NCT07425795 · ClinicalTrials.gov ↗ · Extensive Stage Small Cell Lung Cancer (ES-SCLC)	Phase 2	Recruiting	Chongqing University Cancer Hospital	China
Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast Cancer NCT07457359 · ClinicalTrials.gov ↗ · TNBC, Triple Negative Breast Cancer	Phase 2	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy NCT07463248 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)	Phase 2	Recruiting	Wang Xin	China
Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma NCT07468630 · ClinicalTrials.gov ↗ · Colon Adenocarcinoma	Phase 2	Recruiting	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University	China
Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors NCT07480733 · ClinicalTrials.gov ↗ · Advanced Malignant Solid Tumors	Phase 2	Recruiting	Shanghai Junshi Bioscience Co., Ltd.	China
KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer NCT07481058 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma (ESCC)	Phase 2	Recruiting	Beijing Konruns Pharmaceutical Co., Ltd.	China
Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC NCT07492342 · ClinicalTrials.gov ↗ · Resectable NSCLC, KRAS G12C Mutation, Stage IB-IIIA NSCLC	Phase 2	Recruiting	Jianxing He	China
A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma NCT07492615 · ClinicalTrials.gov ↗ · Gastric Cancer or Gastroesophageal Junction Adenocarcinoma	Phase 2	Recruiting	Fudan University	China
A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer NCT07506109 · ClinicalTrials.gov ↗ · BRAF V600E, Colorectal Cancer, Sintilimab	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine Carcinoma NCT07518602 · ClinicalTrials.gov ↗ · Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)	Phase 2	Recruiting	Sun Yat-sen University	China
Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure NCT07528274 · ClinicalTrials.gov ↗ · NSCLC (Non-small Cell Lung Cancer), NSCLC (Advanced Non-small Cell Lung Cancer)	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
A Multicohort Study of Toripalimab in Combination With Investigator-Selected Chemotherapy for Advanced HER2-Negative Breast Cancer NCT07540533 · ClinicalTrials.gov ↗ · Advanced Breast Cancer	Phase 2	Recruiting	Henan Cancer Hospital	China
A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States NCT07554521 · ClinicalTrials.gov ↗ · Advanced Unresectable Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Advanced Gastroesophageal Adenocarcinoma	Phase 2	Recruiting	BeOne Medicines	USA
Neoadjuvant Tislelizumab + LM-302 + S-1 or Tislelizumab + SOX for CLDN18.2-Positive Gastric/GEJ Adenocarcinoma NCT07569068 · ClinicalTrials.gov ↗ · Gastric or Esophagogastric Junction Adenocarcinoma	Phase 2	Recruiting	Ruijin Hospital	China
Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell Carcinoma NCT07571551 · ClinicalTrials.gov ↗ · Clear Cell RCC	Phase 2	Recruiting	Jinling Hospital, China	China
Short-Course Radiotherapy Followed by Immunotherapy Combined With Chemotherapy for Microsatellite Stable Locally Advanced Rectal Cancer: A Prospective, Randomized, Controlled Phase II Clinical Trial NCT07594925 · ClinicalTrials.gov ↗ · Rectal Cancer	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma NCT07601737 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Head & Neck Cancer	Phase 2	Recruiting	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	China
Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC NCT07609121 · ClinicalTrials.gov ↗ · NSCLC (Non-small Cell Lung Cancer)	Phase 2	Recruiting	Sun Yat-sen University	China
Gut Microbiota Modulation for Immunotherapy Resensitization in Advanced Renal Cell Carcinoma NCT07611825 · ClinicalTrials.gov ↗ · Advanced RCC	Phase 2	Recruiting	Jinling Hospital, China	China
Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC NCT07646639 · ClinicalTrials.gov ↗ · Rectal Cancer, Radiotherapy	Phase 2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBC NCT07647289 · ClinicalTrials.gov ↗ · Muscle-Invasive Bladder Cancer (MIBC)	Phase 2	Recruiting	Peking University Third Hospital	China
A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor and FOLFOX Chemotherapy Versus Long-Course Chemoradiotherapy for High-Risk Locally Advanced pMMR/MSS Lower Rectal Adenocarcinoma (STAR Trial) NCT07669220 · ClinicalTrials.gov ↗ · Rectal Adenocarcinoma, High-risk Locally Advanced, Short-course Radiotherapy (SCRT)	Phase 2	Recruiting	Sixth Affiliated Hospital, Sun Yat-sen University	China
A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors NCT07669415 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 2	Recruiting	LaNova Medicines Limited	China
Intensified Adjuvant Therapy for High-Risk Newly Diagnosed Glioblastoma With Subtotal Resection or Short-Term Progression NCT07670026 · ClinicalTrials.gov ↗ · Glioblastoma	Phase 2	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma NCT07700667 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	China
Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer NCT07717242 · ClinicalTrials.gov ↗ · Bladder Urothelial Carcinoma, Bladder Cancer	Phase 2	Recruiting	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial NCT07722754 · ClinicalTrials.gov ↗ · Colorectal Neoplasms Malignant, Neoplasm, Metastatic	Phase 2	Recruiting	Guangdong Provincial People's Hospital	China
SABR Combined With Axitinib and Toripalimab for Oligometastatic Renal Cell Carcinoma NCT07744932 · ClinicalTrials.gov ↗ · Oligometastatic Clear Cell Renal Cell Carcinoma	Phase 2	Recruiting	Hebei Medical University Fourth Hospital	China
Adjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLC NCT07748325 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Adjuvant Therapy, Immune Checkpoint Inhibitors	Phase 2	Recruiting	Sichuan University	China
Interferon Gamma Plus Camrelizumab as Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma NCT07787273 · ClinicalTrials.gov ↗ · Locally Advanced Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy, Camrelizumab	Phase 2	Recruiting	Hefei Cancer Hospital of the Chinese Academy of Sciences	China
Liposomal Irinotecan Plus 5-FU/LV and Sintilimab With Sequential SBRT for Locally Advanced Biliary Tract Cancer NCT07797816 · ClinicalTrials.gov ↗ · Biliary Tract Cancer	Phase 2	Recruiting	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	China
Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Cancer NCT07811752 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	Shanghai Chest Hospital	China
A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC NCT07815223 · ClinicalTrials.gov ↗ · SCLC, Limited Stage	Phase 2	Recruiting	Yantai Yuhuangding Hospital	China
Sintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract Cancer NCT07831993 · ClinicalTrials.gov ↗ · Biliary Tract Cancer	Phase 2	Recruiting	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	China
Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer NCT04146298 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Pancreatic Neoplasms, Pancreatic Ductal Adenocarcinoma	Phase 1/2	Recruiting	Changhai Hospital	China
A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast NCT04481763 · ClinicalTrials.gov ↗ · Triple-Negative Breast Cancer	Phase 1/2	Recruiting	Jiangxi Provincial Cancer Hospital	China
APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors NCT04785196 · ClinicalTrials.gov ↗ · Liposarcoma, Advanced Solid Tumor	Phase 1/2	Recruiting	Ascentage Pharma Group Inc.	China
Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer NCT05218889 · ClinicalTrials.gov ↗ · Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreas Cancer	Phase 1/2	Recruiting	Chinese PLA General Hospital	China
Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab NCT05319639 · ClinicalTrials.gov ↗ · Gastric Cancer Stage IV	Phase 1/2	Recruiting	Fujian Cancer Hospital	China
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) NCT05431270 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma	Phase 1/2	Recruiting	Phanes Therapeutics	USA
A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors NCT05615974 · ClinicalTrials.gov ↗ · Malignant Tumors	Phase 1/2	Recruiting	LaNova Medicines Limited	China
Genotype-guided Treatment in Newly Diagnosed PTCL NCT05675813 · ClinicalTrials.gov ↗ · Peripheral T Cell Lymphoma	Phase 1/2	Recruiting	Ruijin Hospital	China
IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors NCT05699811 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Solid Tumors	Phase 1/2	Recruiting	Chinese PLA General Hospital	China
LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer NCT05886439 · ClinicalTrials.gov ↗ · Lung Cancer	Phase 1/2	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors NCT05941507 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1/2	Recruiting	LigaChem Biosciences, Inc.	USA
IN10018 Combination Therapy in Treatment-naïve ES-SCLC NCT06030258 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Extensive Stage	Phase 1/2	Recruiting	InxMed (Shanghai) Co., Ltd.	China
A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors NCT06038396 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1/2	Recruiting	RemeGen Co., Ltd.	China
9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer NCT06079112 · ClinicalTrials.gov ↗ · Advanced Urothelial Carcinoma	Phase 1/2	Recruiting	Mabwell (Shanghai) Bioscience Co., Ltd.	China
Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors NCT06088004 · ClinicalTrials.gov ↗ · Solid Tumor, Adult	Phase 1/2	Recruiting	Suzhou Abogen Biosciences Co., Ltd.	China
Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer NCT06093438 · ClinicalTrials.gov ↗ · Cervical Cancer, Induction Chemotherapy, Immunotherapy	Phase 1/2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors NCT06117566 · ClinicalTrials.gov ↗ · Solid Tumor	Phase 1/2	Recruiting	Shanghai Jiatan Pharmatech Co., Ltd	China
Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma NCT06376721 · ClinicalTrials.gov ↗ · Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, T-lymphoblastic Lymphoma	Phase 1/2	Recruiting	Beijing Tongren Hospital	China
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors NCT06425926 · ClinicalTrials.gov ↗ · Melanoma Stage IV, Solid Tumor	Phase 1/2	Recruiting	Georgiamune Inc	USA
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors NCT06427941 · ClinicalTrials.gov ↗ · Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer	Phase 1/2	Recruiting	BeOne Medicines	USA, China
Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC NCT06494943 · ClinicalTrials.gov ↗ · Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma	Phase 1/2	Recruiting	Fudan University	China
A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC) NCT06530251 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 1/2	Recruiting	Akeso	China
Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer NCT06572813 · ClinicalTrials.gov ↗ · Pancreas Cancer	Phase 1/2	Recruiting	First Affiliated Hospital of Zhejiang University	China
First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor. NCT06603844 · ClinicalTrials.gov ↗ · Solid Tumor	Phase 1/2	Recruiting	Corbus Pharmaceuticals Inc.	UK, USA
Immunotherapy Rechallenge in Patients with Solid Tumors in Clinical Trials NCT06612632 · ClinicalTrials.gov ↗ · Cancer	Phase 1/2	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
XELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC/GEJC NCT06742411 · ClinicalTrials.gov ↗ · Gastric (Stomach) Cancer	Phase 1/2	Recruiting	West China Hospital	China
mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer NCT06761027 · ClinicalTrials.gov ↗ · Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer	Phase 1/2	Recruiting	Fujian Provincial Hospital	China
Sintilimab in Combination with Cetuximab and Chemotherapy As First-line Treatment for RAS/BRAF Wild-type Advanced Colorectal Cancer NCT06776757 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 1/2	Recruiting	Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center	China
Clinical Studies for the Treatment of Advanced Solid Tumors NCT06825494 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1/2	Recruiting	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	China
A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours NCT06868199 · ClinicalTrials.gov ↗ · Advanced Solid Tumours	Phase 1/2	Recruiting	LaNova Medicines Limited	China
Personalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma NCT06995105 · ClinicalTrials.gov ↗ · Advanced Hepatocellular Carcinoma (HCC)	Phase 1/2	Recruiting	Zhejiang University	China
IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer NCT07025889 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 1/2	Recruiting	Ruijin Hospital	China
A Trial of LBL-024 Monotherapy, LBL-024 Combined With LBL-007 or Toripalimab in Patients With Advanced Melanoma NCT07099430 · ClinicalTrials.gov ↗ · Advanced Melanoma	Phase 1/2	Recruiting	Nanjing Leads Biolabs Co.,Ltd	China
A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors NCT07169994 · ClinicalTrials.gov ↗ · Advanced Solid Tumors, Breast Cancer, Non Small Cell Lung Cancer	Phase 1/2	Recruiting	MediLink Therapeutics (Suzhou) Co., Ltd.	China
A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma. NCT07258979 · ClinicalTrials.gov ↗ · Recurrent or Metastatic Nasopharyngeal Carcinoma	Phase 1/2	Recruiting	MediLink Therapeutics (Suzhou) Co., Ltd.	China
A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer NCT07281976 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer	Phase 1/2	Recruiting	Nanjing Leads Biolabs Co.,Ltd	China
Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC NCT07365592 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 1/2	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors. NCT07392736 · ClinicalTrials.gov ↗ · Solid Tumor	Phase 1/2	Recruiting	Advenchen Laboratories, LLC	China
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments NCT07468071 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation	Phase 1/2	Recruiting	Novartis Pharmaceuticals	China
Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma NCT07502768 · Extranodal NK/T-cell Lymphoma, NK/T-cell Lymphoma, Relapsed or Refractory NK/T-Cell Lymphoma	Phase 1/2	Recruiting	Rong Tao	China
IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors NCT07508761 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1/2	Recruiting	Nanjing Immunophage Biotech Co., Ltd	China
Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab Immunotherapy NCT07561060 · ClinicalTrials.gov ↗ · Rectal Cancer	Phase 1/2	Recruiting	Fudan University	China
Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation NCT05504278 · ClinicalTrials.gov ↗ · Advanced Non-Small Cell Lung Cancer	Phase 1	Recruiting	Innovent Biologics (Suzhou) Co. Ltd.	China
Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer NCT05979818 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Propranolol	Phase 1	Recruiting	Second Xiangya Hospital of Central South University	China
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors NCT05981703 · ClinicalTrials.gov ↗ · Advanced Solid Tumor, Solid Tumor	Phase 1	Recruiting	BeOne Medicines	USA, China
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors NCT06233942 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1	Recruiting	BeOne Medicines	USA, China
Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors NCT06349837 · ClinicalTrials.gov ↗ · Solid Tumor	Phase 1	Recruiting	Sichuan University	China
Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer NCT06431685 · ClinicalTrials.gov ↗ · NSCLC, Low Dose Radiotherapy, PD-1 Inhibitor	Phase 1	Recruiting	Sichuan University	China
EVM16 Injection as a Single and Combination With Tislelizumab in Solid Tumors NCT06541639 · ClinicalTrials.gov ↗ · Advanced or Recurrent Solid Tumors	Phase 1	Recruiting	Peking University	China
A Study of BG-C477 in Participants With Advanced Solid Tumors NCT06596473 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1	Recruiting	BeOne Medicines	USA, China
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors NCT06657144 · Metastatic Solid Tumor, Advanced Solid Tumor	Phase 1	Recruiting	Coherus Oncology, Inc.	USA, China
A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus NCT06741982 · ClinicalTrials.gov ↗ · HNSCC, Lysogenic HSV Virus, Neoadjuvant Therapy	Phase 1	Recruiting	West China Hospital	China
LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis NCT06848465 · ClinicalTrials.gov ↗ · Colorectal Cancer, Liver Metastasis, LDRT	Phase 1	Recruiting	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University	China
Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC NCT06868732 · ClinicalTrials.gov ↗ · Advanced Non-small Cell Lung Cancer	Phase 1	Recruiting	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	China
Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-refractory Muscle-invasive Bladder Cancer NCT06916494 · ClinicalTrials.gov ↗ · Muscle Invasive Bladder Cancer	Phase 1	Recruiting	First Affiliated Hospital of Chongqing Medical University	China
A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC NCT06969612 · ClinicalTrials.gov ↗ · NSCLC (Advanced Non-small Cell Lung Cancer)	Phase 1	Recruiting	Peking University Cancer Hospital & Institute	China
A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors NCT07414836 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1	Recruiting	BeOne Medicines	USA, China
Study of ABO2102 in KRAS-Mutated Solid Tumors NCT07455617 · ClinicalTrials.gov ↗ · Advanced / Metastatic Solid Tumor	Phase 1	Recruiting	Suzhou Abogen Biosciences Co., Ltd.	China
A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BRII-5395 in Combination With Sintilimab and Bevacizumab in Advanced Hepatitis B Virus Related Hepatocellular Carcinoma NCT07557251 · ClinicalTrials.gov ↗ · Advanced HBV-Related Hepatocellular Carcinoma	Phase 1	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Au-TMP and Radiotherapy for Advanced Melanoma With Anti-PD-1 Therapy NCT07562841 · ClinicalTrials.gov ↗ · Advanced Melanoma	Phase 1	Recruiting	West China Hospital	China
Intranasal WSK-IM05 Vaccine Plus Tislelizumab as Neoadjuvant Therapy for HPV+ OPSCC NCT07565740 · ClinicalTrials.gov ↗ · HPV-positive Oropharyngeal Squamous Cell Carcinoma	Phase 1	Recruiting	West China Hospital	China
Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck Tumors NCT07625423 · ClinicalTrials.gov ↗ · Head & Neck Cancer, Nasopharyngeal Cancinoma (NPC)	Phase 1	Recruiting	West China Hospital	China
Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Sintilimab in Clinical Practice Among Chinese Patients NCT04840355 · ClinicalTrials.gov ↗ · Immune Related Adverse Events, PD-1	Observational	Recruiting	Guohui Li	China
Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma NCT05707819 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma, Sintilimab	Observational	Recruiting	Cancer Hospital of Guangxi Medical University	China
A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer NCT06485271 · ClinicalTrials.gov ↗ · Gastric Cancer, RWS, PD-1 Immunotherapy	Observational	Recruiting	Changzhi People's Hospital Affiliated to Changzhi Medical College	China
A Prospective Cohort Study on the Treatment of Locally Advanced Gastric Cancer NCT06760858 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastroesophageal Junction Cancer	Observational	Recruiting	Southwest Hospital, China	China
Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration NCT06991790 · ClinicalTrials.gov ↗ · TNBC	Observational	Recruiting	Peking University Cancer Hospital & Institute	China
Efficacy and Safety of Tislelizumab Plus Chemotherapy as Conversion Therapy in Unresectable Locally Advanced ESCC NCT07549100 · ClinicalTrials.gov ↗ · Locally Advanced Esophageal Squamous Cell Carcinoma	Observational	Recruiting	Shandong Provincial Hospital	China
Study on MRD Prediction of Efficacy of Toripalimab in the Treatment of High-risk Recurrent Renal Carcinoma NCT07657325 · ClinicalTrials.gov ↗ · Renal Cell Carcinoma (RCC)	Observational	Recruiting	Tianjin Medical University Second Hospital	China
PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT NCT05772273 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Not applicable	Recruiting	The First Affiliated Hospital of Soochow University	China
Toripalimab Plus Actinomycin-D as Fist-Line Treatment for GTN With FIGO Score 5-6 NCT06028672 · ClinicalTrials.gov ↗ · Gestational Trophoblastic Neoplasia	Not applicable	Recruiting	Peking Union Medical College Hospital	China
bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC NCT06061276 · ClinicalTrials.gov ↗ · Liver Diseases, Hepatocellular Carcinoma, Immunotherapy	Not applicable	Recruiting	Sun Yat-sen University	China
Toripalimab Combined With Definitive CCRT for LACC Patients NCT06256224 · ClinicalTrials.gov ↗ · Cervical Cancer, Chemoradiotherapy, Immunotherapy	Not applicable	Recruiting	Ruijin Hospital	China
XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer NCT06353646 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Not applicable	Recruiting	Wu Wenming	China
A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC. NCT06371274 · ClinicalTrials.gov ↗ · Triple-negative Breast Cancer	Not applicable	Recruiting	First Affiliated Hospital of Zhejiang University	China
PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer NCT06549855 · ClinicalTrials.gov ↗ · Endometrial Cancer, Endometrioid Carcinoma, Mismatch Repair Deficiency	Not applicable	Recruiting	Peking University People's Hospital	China
Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer NCT07068542 · ClinicalTrials.gov ↗ · Advanced Thyroid Carcinoma, Radioiodine-refractory Differentiated Thyroid Cancer, Poorly Differentiated Thyroid Carcinoma	Not applicable	Recruiting	Zhejiang Provincial People's Hospital	China
Study on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular Carcinoma NCT07243691 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Not applicable	Recruiting	Sir Run Run Shaw Hospital	China
SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC NCT07474103 · Rectal Cancer, Adenocarcinoma	Not applicable	Recruiting	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	China
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction NCT06951841 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer	Phase 4	Not yet open	China Medical University, China	China
Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study NCT07010393 · ClinicalTrials.gov ↗ · Thyroid Neoplasms	Phase 4	Not yet open	Fujian Medical University	China
A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular Invasion NCT07790419 · ClinicalTrials.gov ↗ · Liver Cancer	Phase 4	Not yet open	Zhai Wenlong	China
Sintilimab Plus NCT or NCRT Versus NCRT for ESCC NCT05244798 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 3	Not yet open	Sichuan Cancer Hospital and Research Institute	China
Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes NCT05610332 · ClinicalTrials.gov ↗ · Locally Advanced Gastric Cancer	Phase 3	Not yet open	Fujian Medical University	China
Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion NCT06089369 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 3	Not yet open	Tongji Hospital	China
A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection NCT06089382 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 3	Not yet open	Tongji Hospital	China
Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer NCT06704620 · ClinicalTrials.gov ↗ · Advanced and Metastatic NSCLC	Phase 3	Not yet open	Tianjin Medical University Cancer Institute and Hospital	China
PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma NCT06900218 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma (NPC)	Phase 3	Not yet open	Sun Yat-sen University	China
Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ Cancer NCT07068516 · ClinicalTrials.gov ↗ · Gastric Cancer Stage	Phase 3	Not yet open	Xiangdong Cheng	China
Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer NCT07132008 · ClinicalTrials.gov ↗ · Colonic Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors	Phase 3	Not yet open	First Affiliated Hospital of Guangxi Medical University	China
Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer NCT07383116 · ClinicalTrials.gov ↗ · Non Squamous Non-small Cell Lung Cancer	Phase 3	Not yet open	Shanghai Huaota Biopharmaceutical Co., Ltd.	China
Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma NCT07445295 · ClinicalTrials.gov ↗ · Metastatic Pancreatic Ductal Adenocarcinoma	Phase 3	Not yet open	Chipscreen Biosciences, Ltd.	China
A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma NCT07446335 · ClinicalTrials.gov ↗ · Advanced Esophageal Squamous Cell Carcinoma	Phase 3	Not yet open	The First Affiliated Hospital of Zhengzhou University	China
GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC. NCT07540390 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 3	Not yet open	Sun Yat-sen University	China
Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial NCT07686796 · ClinicalTrials.gov ↗ · Local Advanced Rectal Cancer, PD-1 Inhibitor, PCSK9 Inhibitor	Phase 3	Not yet open	Guangdong Provincial People's Hospital	China
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma NCT07691515 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma (Icc)	Phase 3	Not yet open	Zhejiang Cancer Hospital	China
ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular NCT07813572 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 3	Not yet open	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	China
JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer NCT07823348 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 3	Not yet open	Shanghai Junshi Bioscience Co., Ltd.	China
Neoadjuvant Sintilimab Plus Chemotherapy for cT2N0M0 Oral Squamous Cell Carcinoma NCT07827872 · ClinicalTrials.gov ↗ · Oral Squamous Cell Carcinoma (OSCC), Head and Neck Squamous Cell Carcinoma, Early-stage Oral Cancer	Phase 3	Not yet open	caohaotian	China
Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations NCT07829549 · ClinicalTrials.gov ↗ · Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations	Phase 3	Not yet open	RemeGen Co., Ltd.	China
An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC NCT04890522 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma, Metastasis, Chemotherapy	Phase 2/3	Not yet open	Sun Yat-sen University	China
Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer NCT05484024 · ClinicalTrials.gov ↗ · Rectal Neoplasms Malignant, Radiotherapy	Phase 2/3	Not yet open	Chinese Academy of Medical Sciences	China
A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma NCT05976568 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 2/3	Not yet open	Qilu Pharmaceutical Co., Ltd.	China
A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06) NCT07739186 · ClinicalTrials.gov ↗ · Non-squamous Non-small Cell Lung Cancer	Phase 2/3	Not yet open	Sichuan Baili Pharmaceutical Co., Ltd.	China
Bladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic Lymph Node Dissection in Bladder Cancer NCT07756008 · ClinicalTrials.gov ↗ · Bladder Urothelial Carcinoma, Muscle-invasive Bladder Cancer, Bladder Cancer	Phase 2/3	Not yet open	Tianjin Medical University Second Hospital	China
An Adaptive-design Prospective Cohort Study of Watch and Wait Strategy in Patients With Locally Advanced Rectal Cancer NCT04443543 · ClinicalTrials.gov ↗ · Rectal Cancer	Phase 2	Not yet open	Fudan University	China
Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma NCT05502991 · ClinicalTrials.gov ↗ · Glioblastoma	Phase 2	Not yet open	Henan Provincial People's Hospital	China
Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Astrocytoma NCT05518994 · ClinicalTrials.gov ↗ · Astrocytoma of Brain	Phase 2	Not yet open	Henan Provincial People's Hospital	China
Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma NCT05540275 · ClinicalTrials.gov ↗ · Recurrent Glioblastoma	Phase 2	Not yet open	Henan Provincial People's Hospital	China
Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer NCT05562297 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Stage IB, Pancreatic Cancer, Stage IIA, Pancreatic Cancer, Stage IIB	Phase 2	Not yet open	Shanghai Zhongshan Hospital	China
Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma NCT05970627 · ClinicalTrials.gov ↗ · Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Epstein-Barr Virus-Associated Gastric Carcinoma	Phase 2	Not yet open	Yu jiren	China
Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 Mutations NCT06118658 · ClinicalTrials.gov ↗ · Gastric, Colorectal Adenocarcinoma	Phase 2	Not yet open	China Medical University, China	China
A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma NCT06152978 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	Not yet open	Fudan University	China
Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC) NCT06198907 · ClinicalTrials.gov ↗ · Non-Small-Cell Lung Cancer	Phase 2	Not yet open	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Sintilimab Plus FOLFIRI as Second-line Therapy for Patients With HER2-negative Advanced Gastric Cancer NCT06365008 · ClinicalTrials.gov ↗ · Unresectable/Metastatic Gastric Cancer	Phase 2	Not yet open	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment. NCT06374901 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 2	Not yet open	Xiangdong Cheng	China
Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer NCT06423937 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 2	Not yet open	Fudan University	China
Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer NCT06454435 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma	Phase 2	Not yet open	Tianjin Medical University Cancer Institute and Hospital	China
Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy NCT06523049 · ClinicalTrials.gov ↗ · Renal Cell Carcinoma, Immunotherapy, Molecular Targeted Therapy	Phase 2	Not yet open	Hao Zeng	China
Oral Topotecan With Toripalimab for Patients With Endometrial Cancer NCT06548763 · ClinicalTrials.gov ↗ · Endometrial Cancer	Phase 2	Not yet open	Fudan University	China
Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer NCT06554028 · ClinicalTrials.gov ↗ · Laryngeal Cancer, Hypopharynx Cancer, Laryngeal Neoplasms	Phase 2	Not yet open	Henan Cancer Hospital	China
A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk. NCT06630871 · ClinicalTrials.gov ↗ · NMIBC	Phase 2	Not yet open	Fujian Medical University Union Hospital	China
Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma NCT06680115 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma (NPC)	Phase 2	Not yet open	First Affiliated Hospital of Guangxi Medical University	China
Neoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant NSCLC NCT06688656 · ClinicalTrials.gov ↗ · Lung Cancer	Phase 2	Not yet open	Shanghai Chest Hospital	China
Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unresectable Stage III NSCLC NCT06706219 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer (Stage III)	Phase 2	Not yet open	Hunan Province Tumor Hospital	China
JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC NCT06731153 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer (TNBC), Metastatic Breast Cancer	Phase 2	Not yet open	Fudan University	China
Preoperative Chemoradiotherapy and Toripalimab in Locally Recurrent Rectal Cancer NCT06751394 · ClinicalTrials.gov ↗ · Recurrent Rectal Cancer	Phase 2	Not yet open	Sixth Affiliated Hospital, Sun Yat-sen University	China
Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer NCT06759090 · ClinicalTrials.gov ↗ · Metastatic Pancreatic Carcinoma	Phase 2	Not yet open	Zhejiang University	China
PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM NCT06788171 · ClinicalTrials.gov ↗ · Colorectal Cancer Liver Metastasis	Phase 2	Not yet open	Fujian Cancer Hospital	China
Nanocrystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC Cachexia NCT06793228 · ClinicalTrials.gov ↗ · SCLC, Extensive Stage	Phase 2	Not yet open	Henan Cancer Hospital	China
Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC NCT06837948 · ClinicalTrials.gov ↗ · Locally Advanced Non-Small Cell Lung Cancer	Phase 2	Not yet open	Shanghai Pulmonary Hospital, Shanghai, China	China
A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours NCT06873854 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 2	Not yet open	LaNova Medicines Limited	China
Toripalimab Adjuvant Therapy in Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Pathological Complete Response (pCR) NCT06903871 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma Stage II, Esophageal Squamous Cell Carcinoma Stage III	Phase 2	Not yet open	Hebei Medical University Fourth Hospital	China
Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06) NCT06919848 · ClinicalTrials.gov ↗ · Biliary Tract Cancer (BTC)	Phase 2	Not yet open	Fudan University	China
The Effect of Neoadjuvant Chemoimmnotherapy Combined With Node Sparing Radiotherapy for cT3N+ EC NCT06965829 · ClinicalTrials.gov ↗ · Esophageal Cancer Stage III	Phase 2	Not yet open	Shanghai Chest Hospital	China
A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC NCT06977828 · ClinicalTrials.gov ↗ · NSCLC (Non-small Cell Lung Cancer), Neoadjuvant Immunotherapy, Adjuvant Immunotherapy	Phase 2	Not yet open	The First Affiliated Hospital with Nanjing Medical University	China
Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer NCT07018063 · ClinicalTrials.gov ↗ · Gastric (Cardia, Body) Cancer, Stomach Adenocarcinoma, Locally Advanced	Phase 2	Not yet open	zhoujing	China
A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC NCT07038460 · ClinicalTrials.gov ↗ · Resectable Non-small Cell Lung Cancer	Phase 2	Not yet open	Wen-zhao ZHONG	China
A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC NCT07040644 · ClinicalTrials.gov ↗ · Triple Negative Breast Neoplasms	Phase 2	Not yet open	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors NCT07053150 · ClinicalTrials.gov ↗ · Advanced Digestive System Tumor	Phase 2	Not yet open	Tongji Hospital	China
Neoadjuvant and Adjuvant Sintilimab Plus Cetuximab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma NCT07079410 · ClinicalTrials.gov ↗ · Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma, Resectable Oral and Oropharyngeal Squamous Cell Carcinoma	Phase 2	Not yet open	Shanghai Zhongshan Hospital	China
Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Incidental Small Cell Lung Cancer After Radical Resection of Lung Cancer: A Single-Center, Randomized Controlled Clinical Study Protocol Number: LungMate-033 NCT07097948 · ClinicalTrials.gov ↗ · Postoperative Incidental Small Cell Lung Cancer, Toripalimab Adjuvant Therapy Evaluation	Phase 2	Not yet open	Shanghai Pulmonary Hospital, Shanghai, China	China
Radiotherapy Omitting Prophylactic Neck Irradiation With Neoadjuvant and Adjuvant Toripalimab in Nasopharyngeal Carcinoma NCT07110558 · ClinicalTrials.gov ↗ · Nasopharyngeal Cancinoma (NPC)	Phase 2	Not yet open	Sun Yat-sen University	China
Iparomlimab and Tuvonralimab Combined With GC in Advanced ICC NCT07152769 · ClinicalTrials.gov ↗ · Advanced Intrahepatic Cholangiocarcinoma	Phase 2	Not yet open	Fudan University	China
Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer NCT07159217 · ClinicalTrials.gov ↗ · Biliary Tract Cancer, Disitamab Vedotin, Lenvatinib	Phase 2	Not yet open	Peking Union Medical College Hospital	China
Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study NCT07189793 · ClinicalTrials.gov ↗ · Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Carcinoma in Situ of Bladder	Phase 2	Not yet open	First Affiliated Hospital of Wenzhou Medical University	China
Exploration of Sintilimab + Bevacizumab + AG Chemotherapy as First-Line Treatment for Unresectable Advanced/Metastatic Cholangiocarcinoma NCT07328802 · ClinicalTrials.gov ↗ · ORR,OS,PFS	Phase 2	Not yet open	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
Lingual Nerve Disruption to Augment Neoadjuvant Chemoimmunotherapy in Locally Advanced Tongue Cancer NCT07346807 · ClinicalTrials.gov ↗ · Tongue Squamous Cell Carcinoma	Phase 2	Not yet open	Shanghai Zhongshan Hospital	China
Sintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Resectable Hepatocellular NCT07352007 · ClinicalTrials.gov ↗ · HCC	Phase 2	Not yet open	Lei ZHAO	China
Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer NCT07358689 · ClinicalTrials.gov ↗ · NSCLC	Phase 2	Not yet open	Tianjin Medical University Cancer Institute and Hospital	China
A Phase II Study of Utidelone With Toripalimab in Advanced Cervical Cancer NCT07363330 · ClinicalTrials.gov ↗ · Cervical Cancer, Recurrent, Metastatic	Phase 2	Not yet open	Zhongnan Hospital	China
Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer NCT07469306 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer	Phase 2	Not yet open	Fujian Cancer Hospital	China
Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer NCT07469956 · ClinicalTrials.gov ↗ · Pancreatic Cancer Resectable	Phase 2	Not yet open	Sun Yat-sen University	China
Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC NCT07474064 · ClinicalTrials.gov ↗ · Muscle Invasive Bladder Cancer (MIBC)	Phase 2	Not yet open	chenxu	China
Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients NCT07493980 · ClinicalTrials.gov ↗ · NSCLC Stage II	Phase 2	Not yet open	Shanghai Pulmonary Hospital, Shanghai, China	China
Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer NCT07521605 · ClinicalTrials.gov ↗ · Rectal Cancer Patients	Phase 2	Not yet open	Guangdong Provincial People's Hospital	China
Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2 NCT07531979 · ClinicalTrials.gov ↗ · ESCC, Tislelizumab, Chemotherapy	Phase 2	Not yet open	Tianjin Medical University Cancer Institute and Hospital	China
SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cancer NCT07535632 · ClinicalTrials.gov ↗ · Colorectal Neoplasms	Phase 2	Not yet open	Shanghai Zhongshan Hospital	China
Denosumab Strategy for Liver Cancer With Bone Metastases NCT07537972 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC), Bone Metastases	Phase 2	Not yet open	Tongji Hospital	China
Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes NCT07557914 · ClinicalTrials.gov ↗ · HCC - Hepatocellular Carcinoma, Diabetes	Phase 2	Not yet open	Haibo Shao	China
Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC NCT07561983 · ClinicalTrials.gov ↗ · Unresectable Stage III Non-small Cell Lung Cancer, Tislelizumab, Chemotherapy	Phase 2	Not yet open	Sichuan Cancer Hospital and Research Institute	China
A Phase II Study of Sintilimab, Pegaspargase and Selinexor Followed by Radiotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma NCT07574528 · ClinicalTrials.gov ↗ · NKTCL	Phase 2	Not yet open	Sun Yat-sen University	China
Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper Tract Urothelial Carcinoma NCT07584733 · ClinicalTrials.gov ↗ · Upper Tract Urothelial Carcinoma	Phase 2	Not yet open	RenJi Hospital	China
SKB315 in Combination Therapy in Patients With Advanced or Metastatic GC/ GEJ Adenocarcinoma NCT07609667 · ClinicalTrials.gov ↗ · Gastroesophageal Junction Adenocarcinoma	Phase 2	Not yet open	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	China
Efficacy and Safety of SBRT Plus Gemcitabine, Cisplatin, and Sintilimab as First-Line Treatment for Unresectable Biliary Tract Cancer NCT07638501 · ClinicalTrials.gov ↗ · Biliary Tract Cancer (BTC)	Phase 2	Not yet open	Eastern Hepatobiliary Surgery Hospital	China
Mannatide Combined With CAPOX and Tislelizumab for Advanced Gastric Cancer. NCT07655661 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma	Phase 2	Not yet open	Ming Liu	China
Sintilimab Plus Gossypol Acetate in Advanced Colorectal Cancer NCT07656766 · ClinicalTrials.gov ↗ · Advanced Colorectal Cancer	Phase 2	Not yet open	Peking University People's Hospital	China
A Study on the Efficacy and Safety of Sintilimab Combined With Ramucirumab and Paclitaxel in the Treatment of Gastric Cancer Patients With Short-term Recurrence After Adjuvant Therapy NCT07669740 · ClinicalTrials.gov ↗ · Gastric Cancer (Diagnosis)	Phase 2	Not yet open	The First Affiliated Hospital with Nanjing Medical University	China
MRG003 Plus Toripalimab Versus Toripalimab as Neoadjuvant Therapy for PD-L1-Positive, Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma NCT07677475 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma	Phase 2	Not yet open	Dongguan People's Hospital	China
SBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreatic Cancer NCT07683221 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 2	Not yet open	Shandong Cancer Hospital and Institute	China
Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study NCT07685704 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, HER2-positive Gastric Cancer	Phase 2	Not yet open	Zhifeng Zhao, PhD	China
Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial NCT07715565 · ClinicalTrials.gov ↗ · Renal Cell Carcinoma (Kidney Cancer), Immunotherapy, Molecular Targeted Therapy	Phase 2	Not yet open	West China Hospital	China
A Single-Arm Study of Sintilimab and Disitamab Vedotin for Locally Advanced Eyelid Sebaceous Gland Carcinoma NCT07740993 · ClinicalTrials.gov ↗ · Sebaceous Gland Carcinoma	Phase 2	Not yet open	West China Hospital	China
Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancer NCT07745790 · ClinicalTrials.gov ↗ · Pancreatic Ductal Adenocarcinoma, Liver Neoplasms, Lung Neoplasms	Phase 2	Not yet open	Ruijin Hospital	China
Radscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer: A Single-Center, Open-Label, Phase II Study NCT07756190 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma (NPC), Metastatic Nasopharyngeal Carcinoma	Phase 2	Not yet open	Sun Yat-sen University	China
GELAD-Based Response-Adapted Treatment for Early-Stage Extranodal NK/T-Cell Lymphoma NCT07768943 · ClinicalTrials.gov ↗ · Natural Killer/T-cell Lymphoma	Phase 2	Not yet open	Fudan University	China
Spatially Fractionated Radiotherapy With Tislelizumab and Chemotherapy for Bulky Stage III NSCLC: A Phase II Trial NCT07775040 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 2	Not yet open	Sichuan Cancer Hospital and Research Institute	China
Induction PD-1 Inhibitor and Chemotherapy Followed by Chemoradiotherapy in Unresectable or Inoperable HPV-negative LA-HNSCC NCT07776340 · ClinicalTrials.gov ↗ · HPV-unrelated Head and Neck Squamous Cell Carcinoma	Phase 2	Not yet open	Fudan University	China
A Multicenter, Prospective, Phase II Study of TROP-2 ADC in Combination With Toripalimab for Resectable Locally Advanced Oral Squamous Cell Carcinoma NCT07778368 · ClinicalTrials.gov ↗ · Oral Squamous Cell Carcinoma (OSCC)	Phase 2	Not yet open	Shanghai East Hospital	China
Paclitaxel Polymeric Micelles and Cisplatin Plus Sintilimab as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma NCT07799077 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	Not yet open	Hebei Medical University Fourth Hospital	China
Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy for Oral or Oropharyngeal Squamous Cell Carcinoma NCT07812467 · ClinicalTrials.gov ↗ · Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (OPSCC)	Phase 2	Not yet open	Shanghai Zhongshan Hospital	China
SBRT Combined With Reduced-Dose Anthracycline Chemotherapy and Toripalimab as Neoadjuvant Therapy for Localized High-Risk Undifferentiated Pleomorphic Sarcoma NCT07817095 · ClinicalTrials.gov ↗ · Undifferentiated Pleomorphic Sarcoma (UPS)	Phase 2	Not yet open	Tianjin Medical University Cancer Institute and Hospital	China
Neoadjuvant Sacituzumab Tirumotecan Plus Toripalimab in Locally Advanced Esophageal Squamous Cell Carcinoma NCT07823270 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	Not yet open	Hebei Medical University Fourth Hospital	China
Newly Emerging Immunotherapy for Pancreatic Cancer Treatment NCT06370754 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 1/2	Not yet open	Fudan University	China
Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer NCT06871527 · ClinicalTrials.gov ↗ · Gastric (Stomach) Cancer, Gastric Adenocarcinoma, Fruquintinib	Phase 1/2	Not yet open	Sixth Affiliated Hospital, Sun Yat-sen University	China
Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer. NCT06888674 · ClinicalTrials.gov ↗ · Pancreatic Cancer Resectable	Phase 1/2	Not yet open	Zhejiang University	China
Efficacy Study of Digoxin Combined With Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced Colorectal Cancer NCT07025850 · ClinicalTrials.gov ↗ · Colorectal Carcinoma	Phase 1/2	Not yet open	Fudan University	China
A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer. NCT07559929 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer	Phase 1/2	Not yet open	Hangzhou DAC Biotechnology Co., Ltd.	China
Efficacy and Safety of Immune Checkpoint Inhibitors for Refractory Opportunistic Infections in AIDS NCT07579247 · ClinicalTrials.gov ↗ · HIV, AIDS, Immune Checkpoint Inhibitors	Phase 1/2	Not yet open	Shanghai Public Health Clinical Center	China
Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors NCT07612137 · ClinicalTrials.gov ↗ · Solid Tumor	Phase 1/2	Not yet open	Innovent Biologics (Suzhou) Co. Ltd.	China
PTC-Guided Atorvastatin Plus Axitinib and Toripalimab in Advanced RCC NCT07630363 · ClinicalTrials.gov ↗ · Advanced Renal Cell Carcinoma (RCC), PTC, Atorvastatin	Phase 1/2	Not yet open	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma NCT07761286 · ClinicalTrials.gov ↗ · HCC - Hepatocellular Carcinoma	Phase 1/2	Not yet open	CSPC Megalith Biopharmaceutical Co.,Ltd.	China
NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC NCT07318636 · ClinicalTrials.gov ↗ · Resectable Non-small Cell Lung Cancer	Phase 1	Not yet open	The First Affiliated Hospital of Guangzhou Medical University	China
PIN in Combination With Sintilimab in Previously Treated pMMR/MSS CRC With Hepatic Metastases NCT07411781 · ClinicalTrials.gov ↗ · Colorectal Cancer, Adult	Phase 1	Not yet open	Chinese PLA General Hospital	China
A Clinical Study for the Safety and Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer NCT07550842 · ClinicalTrials.gov ↗ · Small Cell Carcinoma of Lung	Phase 1	Not yet open	Shanghai Best-Link Bioscience, LLC	China
HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion NCT07699757 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma (mPDAC), Advanced Solid Tumors	Phase 1	Not yet open	Haisco Pharmaceutical Group Co., Ltd.	China
A Study to Evaluate the Efficacy and Safety of Intravesical Instillation of Disitamab Vedotin Combined With Toripalimab in Patients With HER2-Positive High-Risk Non-Muscle Invasive Bladder Cancer Who Are BCG-Naïve or Have BCG Failure NCT07783815 · ClinicalTrials.gov ↗ · Bladder Cancer	Phase 1	Not yet open	Xiangya Hospital of Central South University	China
A Real-world Study Evaluating the Usage of Camrelizumab in Chinese Patients With Advanced Esophageal Cancer NCT04616040 · ClinicalTrials.gov ↗ · Esophageal Cancer	Observational	Not yet open	Peking University	China
Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC NCT06607926 · ClinicalTrials.gov ↗ · Resectable Non-Small-Cell Lung Cancer	Not applicable	Not yet open	Xuanwu Hospital, Beijing	China
A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer NCT07466901 · ClinicalTrials.gov ↗ · Cervical Cancer, Radical Surgery, Adjuvant Therapy	Not applicable	Not yet open	Jin LI	China
Safety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC NCT07480382 · ClinicalTrials.gov ↗ · Initially Unresectable Hepatocellular Carcinoma	Not applicable	Not yet open	Hong Wu	China
Fasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell Carcinoma NCT07500831 · ClinicalTrials.gov ↗ · Carcinoma, Renal Cell, Metastatic Renal Cell Carcinoma, Advanced Renal Cell Carcinoma	Not applicable	Not yet open	Qilu Hospital of Shandong University	China
To Explore a Single-arm Phase II Study on Intestinal Microbiota Transplantation Combined With Neoadjuvant Immunotherapy and Chemoradiotherapy for Locally Advanced Rectal Cancer Under MSS/pMMR NCT07738042 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer (LARC)	Not applicable	Not yet open	Tianjin Medical University Cancer Institute and Hospital	China
Sequential PD-1 Antibody and Pegylated Interferon Therapy for Nucleos(t)Ide Analogue-suppressed Chronic Hepatitis B NCT07809165 · ClinicalTrials.gov ↗ · Chronic Hepatitis B	Not applicable	Not yet open	Beijing 302 Hospital	China
Intestinal Microbiota Transplantation, Radiochemotherapy and Sintilimab in Localized Advanced Colon Cancer NCT06931808 · ClinicalTrials.gov ↗ · Localized Advanced Rectal Adenocarcinoma	Phase 4	By invitation	First Affiliated Hospital of Ningbo University	China
Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma NCT07312578 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	By invitation	Peking University	China
Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC NCT07353294 · ClinicalTrials.gov ↗ · Bladder Urothelial Carcinoma, Lymph Node Metastasis	Phase 1	By invitation	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
Efficacy and Safety of Sintilimab Combined with Platinum-containing Double-agent Chemotherapy in First-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer in Elderly Patients NCT06883136 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Observational	By invitation	Qianfoshan Hospital	China
Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer NCT06866548 · ClinicalTrials.gov ↗ · mCRPC	Phase EARLY_PHASE1	Active, closed	Shanghai Changzheng Hospital	China
Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma NCT03967977 · ClinicalTrials.gov ↗ · Urothelial Carcinoma	Phase 3	Active, closed	BeiGene	China
A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib NCT04170283 · ClinicalTrials.gov ↗ · B-cell Malignancies	Phase 3	Active, closed	BeOne Medicines	UK, USA, China
A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation NCT04639180 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)	Phase 3	Active, closed	Jiangsu HengRui Medicine Co., Ltd.	China
Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC. NCT05043688 · ClinicalTrials.gov ↗ · Resectable Esophageal Squamous Cell Carcinoma	Phase 3	Active, closed	Zhigang Li	China
Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer NCT05116462 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 3	Active, closed	Innovent Biologics (Suzhou) Co. Ltd.	China
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers NCT05152147 · ClinicalTrials.gov ↗ · Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma	Phase 3	Active, closed	Jazz Pharmaceuticals	Ireland, UK, India, China
Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer NCT05171660 · ClinicalTrials.gov ↗ · Colorectal Cancer Stage IV	Phase 3	Active, closed	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial NCT05198609 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 3	Active, closed	Sun Yat-sen University	China
Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma NCT05211232 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 3	Active, closed	Sun Yat-sen University	China
A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma NCT05320692 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 3	Active, closed	Jiangsu HengRui Medicine Co., Ltd.	China
ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma NCT06206733 · ClinicalTrials.gov ↗ · Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma	Phase 3	Active, closed	AskGene Pharma, Inc.	China
Node-sparing Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Rectal Cancer NCT06507371 · ClinicalTrials.gov ↗ · Rectal Cancer	Phase 3	Active, closed	Sir Run Run Shaw Hospital	China
Using ctDNA to Guide Treatment Decisions for Stage III Gastric Cancer NCT06939439 · ClinicalTrials.gov ↗ · Gastric Cancer Stage III	Phase 3	Active, closed	The First Affiliated Hospital with Nanjing Medical University	China
Sintilimab Combined With Chemotherapy Induction Therapy Followed by CCRT vs. CCRT for Esophageal Cancer: A Randomized Controlled Phase Ⅲ Clinical Study NCT07306663 · ClinicalTrials.gov ↗ · Esophageal Cancer	Phase 3	Active, closed	Jiangsu Cancer Institute & Hospital	China
Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma NCT04521153 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Immunotherapy, Molecular Targeted Therapy	Phase 2/3	Active, closed	Shanghai Zhongshan Hospital	China
Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2) NCT05522231 · ClinicalTrials.gov ↗ · Advanced Renal Cell Carcinoma	Phase 2/3	Active, closed	Hutchmed	China
A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer NCT05980481 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 2/3	Active, closed	RemeGen Co., Ltd.	China
A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer NCT06984588 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Phase 2/3	Active, closed	TJ Biopharma Co., Ltd.	China
Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma NCT04067037 · ClinicalTrials.gov ↗ · Classical Hodgkin Lymphoma	Phase 2	Active, closed	Henan Cancer Hospital	China
Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer NCT04304209 · ClinicalTrials.gov ↗ · Colorectal Cancer Stage II, Colorectal Cancer Stage III	Phase 2	Active, closed	Sun Yat-sen University	China
Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02) NCT04515615 · ClinicalTrials.gov ↗ · Gastric Cancer Stage III	Phase 2	Active, closed	Yu jiren	China
Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma NCT04517214 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 2	Active, closed	Fudan University	China
A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) NCT04734262 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer	Phase 2	Active, closed	Fudan University	China
PD-1 Antibody Following Preoperative Chemoradiotherapy for Locally Advanced pMMR/MSS Rectal Cancer NCT04833387 · Colorectal Carcinoma	Phase 2	Active, closed	Sun Yat-sen University	China
Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer NCT05177068 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 2	Active, closed	Henan Cancer Hospital	China
Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma NCT05201859 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 2	Active, closed	Sun Yat-sen University	China
Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma NCT05220267 · ClinicalTrials.gov ↗ · Non Clear Cell Renal Carcinoma	Phase 2	Active, closed	Sun Yat-sen University	China
SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage II to III Non-small Cell Lung Cancer NCT05319574 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung	Phase 2	Active, closed	Sun Yat-sen University	China
The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC NCT05343325 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma, Neoadjuvant Treatment	Phase 2	Active, closed	Fifth Affiliated Hospital, Sun Yat-Sen University	China
Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002) NCT05520619 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma, Locally Advanced Esophageal Squamous Cell Carcinoma	Phase 2	Active, closed	Sun Yat-sen University	China
SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma NCT05524168 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 2	Active, closed	Sun Yat-sen University	China
Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer NCT05531123 · ClinicalTrials.gov ↗ · Bladder Cancer	Phase 2	Active, closed	Fudan University	China
First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer NCT05586061 · ClinicalTrials.gov ↗ · HER2-positive Gastric Cancer	Phase 2	Active, closed	Qilu Hospital of Shandong University	China
Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study NCT05602935 · Stomach Neoplasms, Digestive System Neoplasms, Neoplasms	Phase 2	Active, closed	The Second Affiliated Hospital of Fujian Medical University	China
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer NCT05635708 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer	Phase 2	Active, closed	BeiGene	USA, China
Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma NCT05715931 · ClinicalTrials.gov ↗ · Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, HER2-positive Gastric Cancer	Phase 2	Active, closed	Yu jiren	China
Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01) NCT05724329 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinomas	Phase 2	Active, closed	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma NCT05813626 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 2	Active, closed	Zhejiang Cancer Hospital	China
Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume Local Advanced NSCLC NCT05888402 · ClinicalTrials.gov ↗ · Local Advanced Non-small Cell Lung Cancer	Phase 2	Active, closed	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation NCT05975307 · ClinicalTrials.gov ↗ · Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy	Phase 2	Active, closed	Sun Yat-sen University	China
Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT) NCT06009861 · ClinicalTrials.gov ↗ · Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma	Phase 2	Active, closed	Peking University Hospital of Stomatology	China
Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer NCT06056804 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer	Phase 2	Active, closed	Beijing Friendship Hospital	China
Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer NCT06124378 · ClinicalTrials.gov ↗ · Colonic Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors	Phase 2	Active, closed	First Affiliated Hospital of Guangxi Medical University	China
A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC) NCT06378177 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma	Phase 2	Active, closed	Lyvgen Biopharma Holdings Limited	China
Toripalimab for High-risk Locally Advanced Cervical Cancer NCT06416696 · ClinicalTrials.gov ↗ · Cervical Cancers	Phase 2	Active, closed	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma NCT06447636 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastro Esophageal Junction Cancer	Phase 2	Active, closed	Fudan University	China
Neoadjuvant Short-Course Radiotherapy Followed by CAPOX Plus PD-1 Antibody and IL-2 in Locally Advanced Rectal Cancer (PRIDE01) NCT06577194 · ClinicalTrials.gov ↗ · Rectal Cancer, Advanced Solid Tumor	Phase 2	Active, closed	The First Affiliated Hospital with Nanjing Medical University	China
Neoadjuvant Toripalimab Plus Docetaxel and Carboplatin in Patients With Localized TNBC (NeoTOP) NCT06618014 · ClinicalTrials.gov ↗ · Breast Cancer, Triple Negative Breast Cancer	Phase 2	Active, closed	Sun Yat-sen University	China
Tislelizumab Combined With SBRT for the Treatment of Head and Neck Squamous Cell Carcinoma NCT06673693 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma (HNSCC), HNSCC	Phase 2	Active, closed	Sun Yat-sen University	China
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma NCT06679985 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 2	Active, closed	Coherus Oncology, Inc.	USA, China
Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer NCT06693128 · ClinicalTrials.gov ↗ · Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma	Phase 2	Active, closed	Ruijin Hospital	China
Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer NCT06717464 · ClinicalTrials.gov ↗ · Gallbladder Cancer, Hilar Cholangiocarcinoma, Distal Cholangiocarcinoma	Phase 2	Active, closed	Tianjin Medical University Cancer Institute and Hospital	China
A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer NCT07005336 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Phase 2	Active, closed	TJ Biopharma Co., Ltd.	China
Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma NCT07047001 · ClinicalTrials.gov ↗ · Renal Cell Carcinoma (RCC), Adjuvant	Phase 2	Active, closed	Dong Wen	China
Clinical Study on the Safety and Relationship of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma NCT07127497 · ClinicalTrials.gov ↗ · Pathological Complete Response, Rectal Cancer, Neoadjuvant Chemoimmunotherapy	Phase 2	Active, closed	The First Affiliated Hospital of Anhui Medical University	China
Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy NCT07471815 · ClinicalTrials.gov ↗ · Breast Cancer Triple Negative Breast Cancer	Phase 2	Active, closed	Harbin Medical University	China
Sintilimab Combined With Ipilimumab (N01) Plus AG as First-line Therapy for uBTC. NCT07654530 · ClinicalTrials.gov ↗ · Biliary Tract Cancers (BTC)	Phase 2	Active, closed	Tianjin Medical University Cancer Institute and Hospital	China
Induction Chemoimmunotherapy Followed by Deescalated Definitive Radiotherapy in Head and Neck Cancer NCT07791602 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Cancer, HNSCC	Phase 2	Active, closed	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
CapeOx Combined With Anti-PD1 Antibody Plus Dihydroartemisinin as Neoadjuvant or Conversion Therapy for Microsatellite Stable Locally Advanced and Metastatic Colorectal Cancer NCT07801352 · ClinicalTrials.gov ↗ · Locally Advanced Colorectal Cancer, Metastatic Colorectal Cancer	Phase 2	Active, closed	Shanghai Changzheng Hospital	China
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation NCT04699188 · ClinicalTrials.gov ↗ · KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal	Phase 1/2	Active, closed	Novartis Pharmaceuticals	USA, China
Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma. NCT05176002 · ClinicalTrials.gov ↗ · Esophageal Neoplasm, Immunotherapy, Radiotherapy	Phase 1/2	Active, closed	Fujian Medical University Union Hospital	China
A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors NCT05518045 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1/2	Active, closed	LaNova Medicines Limited	China
A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer NCT05609370 · ClinicalTrials.gov ↗ · Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer	Phase 1/2	Active, closed	BeiGene	USA, China
Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors NCT05651022 · ClinicalTrials.gov ↗ · Solid Tumor, Adult, HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer)	Phase 1/2	Active, closed	Indaptus Therapeutics, Inc	USA
A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors. NCT05661955 · ClinicalTrials.gov ↗ · Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma	Phase 1/2	Active, closed	BeiGene	China
Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors NCT06220318 · ClinicalTrials.gov ↗ · Solid Tumor	Phase 1/2	Active, closed	Fujian Haixi Pharmaceuticals Co., Ltd.	China
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors NCT06771622 · ClinicalTrials.gov ↗ · Solid Cancer	Phase 1/2	Active, closed	FBD Biologics Limited	China
A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma NCT07010120 · ClinicalTrials.gov ↗ · HNSCC, Lysogenic HSV Virus, Neoadjuvant Therapy	Phase 1/2	Active, closed	West China Hospital	China
HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study NCT05167071 · ClinicalTrials.gov ↗ · Solid Tumors, Neuroendocrine Tumors, CRC	Phase 1	Active, closed	Harbour BioMed (Guangzhou) Co. Ltd.	China
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors NCT05238883 · ClinicalTrials.gov ↗ · Gastric Cancer, Renal Cell Carcinoma, Melanoma	Phase 1	Active, closed	HiFiBiO Therapeutics	USA
A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors NCT05502393 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1	Active, closed	Shanghai Junshi Bioscience Co., Ltd.	China
Study of CHS-114 in Participants With Advanced Solid Tumors NCT05635643 · ClinicalTrials.gov ↗ · Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma	Phase 1	Active, closed	Coherus Oncology, Inc.	USA
A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors NCT05789069 · Renal Cell Carcinoma, Melanoma, Non Small Cell Lung Cancer	Phase 1	Active, closed	HiFiBiO Therapeutics	USA
Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors NCT06571422 · ClinicalTrials.gov ↗ · Advanced Malignant Solid Tumors	Phase 1	Active, closed	Shanghai Junshi Bioscience Co., Ltd.	China
HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma NCT05621499 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Not applicable	Active, closed	Tianjin Medical University Cancer Institute and Hospital	China
The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients NCT06357806 · ClinicalTrials.gov ↗ · Chronic Hepatitis B	Not applicable	Active, closed	Beijing 302 Hospital	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Tislelizumab across our data

Ireland · EU · US

The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.

Licensed in Ireland (HPRA)

1 single-substance product containing Tislelizumab on the HPRA medicines list.

Tevimbra 100 mg concentrate for solution for infusionBeiGene Ireland Limited · EU/1/23/1758/001-002

All 1 Irish product →

Supply shortages

No entry for Tislelizumab in the EMA, FDA or German BfArM shortage lists we track.

EU shortages US shortages German shortages

Conditions studied with Tislelizumab

487 conditions

Nasopharyngeal Carcinoma22 Gastric Cancer21 Hepatocellular Carcinoma20 Esophageal Squamous Cell Carcinoma19 Immunotherapy14 Advanced Solid Tumor13 Colorectal Cancer12 Rectal Cancer12 Neoadjuvant Therapy11 Solid Tumor10 Head and Neck Squamous Cell Carcinoma10 Cervical Cancer10

All 487 conditions

Condition (as registered)	Trials
Nasopharyngeal Carcinoma	22
Gastric Cancer	21
Hepatocellular Carcinoma	20
Esophageal Squamous Cell Carcinoma	19
Immunotherapy	14
Advanced Solid Tumor	13
Colorectal Cancer	12
Rectal Cancer	12
Neoadjuvant Therapy	11
Solid Tumor	10
Head and Neck Squamous Cell Carcinoma	10
Cervical Cancer	10
Hepatocellular Carcinoma (HCC)	8
Non-Small Cell Lung Cancer	8
Breast Cancer	8
Gastroesophageal Junction Adenocarcinoma	7
Radiotherapy	7
Esophageal Cancer	7
Non Small Cell Lung Cancer	6
Urothelial Carcinoma	6
Chemotherapy	6
Pancreatic Cancer	6
Nasopharyngeal Carcinoma (NPC)	6
Renal Cell Carcinoma	5
HCC - Hepatocellular Carcinoma	5
Advanced Solid Tumors	5
Locally Advanced Esophageal Squamous Cell Carcinoma	5
Gastric Adenocarcinoma	5
Immune Checkpoint Inhibitors	5
Oral Squamous Cell Carcinoma	5
PD-1 Inhibitor	5
Lung Cancer	5
Neoadjuvant Chemoimmunotherapy	5
Oral Squamous Cell Carcinoma (OSCC)	5
HCC	4
Tislelizumab	4
NSCLC (Non-small Cell Lung Cancer)	4
Bladder Cancer	4
HER2-positive Gastric Cancer	4
HNSCC	4
Intrahepatic Cholangiocarcinoma	4
NSCLC	4
Sintilimab	4
Melanoma	3
Pancreatic Ductal Adenocarcinoma	3
Solid Tumor, Adult	3
Triple-negative Breast Cancer	3
Colorectal Carcinoma	3
Head & Neck Cancer	3
Classical Hodgkin Lymphoma	3
Head and Neck Cancer	3
Bladder Urothelial Carcinoma	3
Esophageal Squamous Cell Carcinoma (ESCC)	3
Advanced Hepatocellular Carcinoma	3
Adjuvant Therapy	3
Oropharyngeal Squamous Cell Carcinoma	3
Metastatic Colorectal Cancer	3
Immune Checkpoint Inhibitor	3
Biliary Tract Cancer	3
Gestational Trophoblastic Neoplasia	3
Mismatch Repair Deficiency	3
Triple Negative Breast Cancer	3
Nasopharyngeal Cancinoma (NPC)	3
Triple Negative Breast Cancer (TNBC)	3
Adenocarcinoma of the Stomach	3
Adenocarcinoma of Esophagogastric Junction	3
Chemoradiotherapy	3
Molecular Targeted Therapy	3
Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type	3
Carcinoma, Non-Small-Cell Lung	2
Esophageal Neoplasms	2
Concurrent Chemoradiotherapy	2
Muscle Invasive Bladder Cancer (MIBC)	2
NSCLC (Advanced Non-small Cell Lung Cancer)	2
Upper Tract Urothelial Carcinoma	2
Microsatellite Instability High	2
Metastatic Breast Cancer	2
Resectable NSCLC	2
Glioblastoma	2
Colonic Neoplasms	2
Gastric Cancer Stage III	2
Head and Neck Squamous Cell Carcinoma (HNSCC)	2
Neoadjuvant Immunotherapy	2
Advanced Solid Tumour	2
Lysogenic HSV Virus	2
Gastric (Stomach) Cancer	2
Hilar Cholangiocarcinoma	2
Small Cell Lung Cancer	2
Recurrent Glioblastoma	2
Bone Metastases	2
Urinary Bladder Neoplasms	2
Locally Advanced Rectal Cancer	2
Adjuvant Immunotherapy	2
Stomach Neoplasms	2
Pancreatic Neoplasms	2
Advanced Cancer	2
Recurrent Rectal Cancer	2
Advanced Melanoma	2
Advanced Colorectal Cancer	2
TNBC, Triple Negative Breast Cancer	2
Colorectal Cancer Metastatic	2
Advanced Urothelial Carcinoma	2
Renal Cell Carcinoma (RCC)	2
Acral Melanoma	2
PD-1	2
NSCLC Stage II	2
Biliary Tract Cancer (BTC)	2
Advanced Renal Cell Carcinoma	2
Advanced Lung Cancer	2
Endometrial Cancer	2
Advanced Malignant Solid Tumors	2
Pancreatic Cancer Resectable	2
Microsatellite Stable Metastatic Colorectal Cancer	2
Colorectal Cancer Liver Metastasis	2
Locally Advanced Non-Small Cell Lung Cancer	2
Esophagogastric Junction Adenocarcinoma	2
Chronic Hepatitis B	2
Resectable Non-small Cell Lung Cancer	2
Pancreas Cancer	2
Natural Killer/T-cell Lymphoma	2
Digestive System Neoplasms	2
Triple-Negative Breast Cancer	2
Camrelizumab	2
Locally Advanced Cervical Cancer	2
Gastric Neoplasms	1
Gastroesophageal Adenocarcinoma	1
Esophageal Adenocarcinoma	1
B-cell Malignancies	1
Metastatic Gastric Adenocarcinoma	1
NSCLC Stage IV	1
Sarcoma	1
Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer	1
Metastatic Hepatocellular Carcinoma	1
Local Advanced Hepatocellular Carcinoma	1
Alpha-fetoprotein (AFP)-Producing Gastric Cancer	1
Extragonadal Yolk Sac Tumors	1
CRC (Colorectal Cancer)	1
Pancreatic Adenocarcinoma	1
Advanced Unresectable Gastric Adenocarcinoma	1
Advanced Gastroesophageal Adenocarcinoma	1
Non-small Cell Lung Cancer	1
Metastatic Non-small Cell Lung Cancer	1
KRAS G12C Mutant Solid Tumors	1
Carcinoma, Colorectal	1
Cancer of Lung	1
Surufatinib	1
Consolidation Therapy	1
Extranodal NK/T-cell Lymphoma	1
NK/T-cell Lymphoma	1
Relapsed or Refractory NK/T-Cell Lymphoma	1
Hepato Cellular Carcinoma (HCC)	1
Gastroesophageal-junction Cancer	1
Adenocarcinoma	1
Gastric Cancer Stage	1
Rectal Cancer Stage II	1
Rectal Cancer Stage III	1
Solid Tumors	1
Neuroendocrine Tumors	1
CRC	1
Oligodendroglioma	1
Advanced Non-small Cell Lung Cancer	1
Diabetes	1
Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer	1
Advanced Solid Tumors Harboring the KRAS G12C Mutation	1
Locally Advanced or Metastatic Solid Tumors	1
Head &Amp; Neck Squamous Cell Carcinoma	1
Angioimmunoblastic T-Cell Lymphoma Recurrent	1
Angioimmunoblastic T-Cell Lymphoma Refractory	1
HPV-unrelated Head and Neck Squamous Cell Carcinoma	1
HPV-positive Oropharyngeal Squamous Cell Carcinoma	1
Perioperative Immunotherapy	1
Limited Stage Lung Small Cell Carcinoma	1
Resectable Small Cell Lung Cancer	1
Stage III Non-small Cell Lung Cancer	1
Advanced or Recurrent Solid Tumors	1
Biliary Tract Carcinoma	1
Immunotherapy Gastrict Cancer	1
Small Cell Lung Cancer Extensive Stage	1
Double Blind	1
Immunotherapy Esophagus Cancer	1
Lung Cancer (NSCLC)	1
Gastric Cancer Stage IV	1
Peripheral T Cell Lymphoma	1
Locally Advanced Prostate Cancer	1
Oligometastatic Prostate Cancer	1
Child	1
Adolescent	1
Young Adult	1
Neoadjuvant Treatment	1
mCRPC	1
Fruquintinib	1
Non-mucosal Melanoma	1
SCLC, Limited Stage	1
Liver Metastasis	1
LDRT	1
Non Squamous Non-small Cell Lung Cancer	1
Lymph Node Metastasis	1
Extensive-stage Small-cell Lung Cancer	1
Gastric or Esophagogastric Junction Adenocarcinoma	1
Cholangiocarcinoma	1
Bile Duct Cancer	1
Recurrent Hepatocellular Carcinoma	1
Esophageal Cancer Stage III	1
Unresectable Stage III Non-small Cell Lung Cancer	1
Chemoembolization, Therapeutic	1
Locally Advanced Unresectable Esophageal Cancer	1
Gastric Carcinoma	1
Initially Unresectable Hepatocellular Carcinoma	1
MCRC	1
New Diagnosed Angioimmunoblastic T-Cell Lymphoma	1
Resectable Non-Small-Cell Lung Cancer	1
ESCC	1
Becotatug Vedotin	1
Locally Advanced Rectal Carcinoma	1
Soft Tissue Sarcomas	1
Angiosarcoma	1
Fibrosarcoma	1
Leiomyosarcoma	1
Astrocytoma of Brain	1
Laryngeal Cancer	1
Hypopharynx Cancer	1
Laryngeal Neoplasms	1
NSCLC Associated With Leptomeningeal Metastases	1
Intrahepatic Cholangiocarcinoma (Icc)	1
Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations	1
Advanced and Metastatic NSCLC	1
SCLC, Extensive Stage	1
Renal Pelvic Carcinoma	1
Kidney-sparing	1
Liver Cancer	1
Non-squamous Non-small Cell Lung Cancer	1
NMIBC	1
Extensive Stage Small Cell Lung Cancer (ES-SCLC)	1
LA HNSCC	1
BCG Vaccine	1
Immunotherapy, Active	1
Multicenter Study	1
Head and Neck Squamous Cell Carcinomas	1
Tongue Squamous Cell Carcinoma	1
Muscle Invasive Bladder Cancer	1
Microsatellite Stable Colorectal Carcinoma	1
Nab-paclitaxel	1
Oropharyngeal Squamous Cell Carcinoma (OPSCC)	1
Squamous Cell Carcinoma of External Auditory Canal	1
Locally Advanced Tumor	1
Locally Advanced Colorectal Cancer	1
Gastric Cancer, Gastroesophageal Junction Cancer	1
Advanced Thyroid Carcinoma	1
Radioiodine-refractory Differentiated Thyroid Cancer	1
Poorly Differentiated Thyroid Carcinoma	1
Linitis Plastica of Stomach	1
Intrahepatic Cholangiocellular Carcinoma	1
Gastric	1
Colorectal Adenocarcinoma	1
Advanced Non-squamous Non-small-cell Lung Cancer	1
Metastatic Non-squamous Non Small Cell Lung Cancer	1
Melanoma Stage IV	1
Metastatic Solid Tumor	1
Nasopharyngeal Cancer Recurrent	1
Paget Disease, Extramammary	1
Scrotum Disease	1
Metastatic Pancreatic Ductal Adenocarcinoma	1
PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer	1
Hodgkin Lymphoma	1
Local Advanced Non-small Cell Lung Cancer	1
Triple Negative Breast Neoplasms	1
Liposarcoma	1
Induction Chemotherapy	1
Disitamab Vedotin	1
Lenvatinib	1
Gallbladder Cancer	1
Distal Cholangiocarcinoma	1
Recurrent	1
Metastatic	1
Muscle-Invasive Bladder Cancer (MIBC)	1
Esophageal Squamous Cell Carcinoma Stage II	1
Esophageal Squamous Cell Carcinoma Stage III	1
Undifferentiated Pleomorphic Sarcoma (UPS)	1
HER2-expressing	1
Stage IB-IIIB NSCLC	1
Stage IIB-III NSCLC	1
ER+/HER2- Breast Cancer	1
Advanced Esophageal Squamous Cell Carcinoma	1
Cancer	1
Probiotics	1
PD-1 Treatment	1
Cervical Cancers	1
Malignant Neoplasms of Digestive Organs	1
Advanced RCC	1
Advanced Renal Cell Carcinoma (RCC)	1
PTC	1
Atorvastatin	1
Targeted Therapy Combined With Immunotherapy	1
Early Low Rectal Cancer	1
Postoperative Incidental Small Cell Lung Cancer	1
Toripalimab Adjuvant Therapy Evaluation	1
TNBC	1
Melanoma of Skin	1
Stage II Melanoma	1
Soft Tissue Sarcoma	1
MIBC	1
Carcinoma, Transitional Cell	1
Carcinoma in Situ of Bladder	1
Non-Muscle-Invasive Bladder Cancer	1
Oligometastatic Clear Cell Renal Cell Carcinoma	1
Muscle-invasive Bladder Cancer	1
Rectal Adenocarcinoma	1
High-risk Locally Advanced	1
Short-course Radiotherapy (SCRT)	1
Surgery	1
Carcinoma, Renal Cell	1
Metastatic Renal Cell Carcinoma	1
Clear Cell RCC	1
Non-clear Renal Cell Carcinoma	1
Non Small Cell Lung Cancer (Stage III)	1
HR+/HER2- Breast Cancer	1
Malignant Tumors	1
Mismatch Repair-deficient (dMMR)	1
Microsatellite Instability-high (MSI-H)	1
Muscle-Invasive Bladder Carcinoma	1
Programmed Cell Death Protein 1 Inhibitor	1
Advanced Breast Cancer	1
Gastric Type Adenocarcinoma (GAS) With STK11 Mutation	1
Limited-stage Small Cell Lung Cancer (LS-SCLC)	1
Locally Advanced or Metastatic GC and GCJ Adenocarcinoma	1
Advanced Solid Tumours	1
Small Cell Carcinoma of Lung	1
HR-positive,HER2-negative Breast Cancer	1
Solid Cancer	1
Adjuvant	1
Clear Cell Renal Cell Carcinoma	1
Urothelial Carcinoma Bladder	1
Urothelial Carcinoma Recurrent	1
Urothelial Carcinoma of the Renal Pelvis and Ureter	1
Recurrent or Metastatic Nasopharyngeal Carcinoma	1
Locally Advanced Gastric Carcinoma	1
Epstein-Barr Virus-Associated Gastric Carcinoma	1
Metastasis	1
Rectal Cancer, Adenocarcinoma	1
Early-stage Oral Cancer	1
Locally Advanced Oral Squamous Cell Carcinoma	1
Metastatic Nasopharyngeal Carcinoma	1
Advanced Endometrial Cancer	1
Pancreatic Ductal Adenocarcinoma (mPDAC)	1
BRAF V600E	1
MSS (Microsatellite Stable)	1
Colon Adenocarcinoma	1
Adult	1
Non-Small-Cell Lung Cancer	1
KRAS G12C Mutation	1
Stage IB-IIIA NSCLC	1
Gastric (Cardia, Body) Cancer	1
Stomach Adenocarcinoma	1
Locally Advanced	1
Locally Advanced Rectal Cancer (LARC)	1
Lung Squamous Cell Carcinoma	1
Squamous Cell Non-small Cell Lung Cancer	1
Rcctal Cancer	1
Gastric Cancer Metastatic to Regional Lymph Nodes	1
Resectable Gastric/Gastroesophageal Junction Adenocarcinoma	1
Stage IIIb Non-small Cell Lung Cancer	1
Stage IIIC Non-Small Cell Lung Cancer	1
Neuroblastoma	1
Rectal Neoplasms Malignant	1
Mesothelioma, Malignant	1
Mesothelioma, Malignant Pleural	1
Mesothelioma Malignant Advanced	1
Advanced Digestive System Tumor	1
Mucosal Melanoma	1
PD-L1 Positive	1
Renal Cell Carcinoma (Kidney Cancer)	1
Oral Cavity Squamous Cell Carcinoma	1
Colorectal Cancer Stage II	1
Colorectal Cancer Stage III	1
Thyroid Neoplasms	1
Immune Related Adverse Events	1
Liver Neoplasms	1
Lung Neoplasms	1
Rare Tumor	1
Gastric Cancer (Diagnosis)	1
Colorectal Neoplasms Malignant	1
Neoplasm, Metastatic	1
MRD	1
II-IIIB Stages	1
Localized Advanced Rectal Adenocarcinoma	1
Low Dose Radiotherapy	1
Leptomeningeal Metastasis	1
Locally Advanced Pancreatic Cancer	1
Metastatic Pancreatic Cancer	1
Squamous Cell Esophageal Carcinoma	1
Oesophageal Cancer	1
Advanced Intrahepatic Cholangiocarcinoma	1
Colorectal Neoplasms	1
NSCLC Stage III	1
Bevacizimab	1
Gastro Esophageal Junction Cancer	1
Endometrioid Carcinoma	1
Locally Advanced Head and Neck Squamous Cell Carcinoma	1
Propranolol	1
Non Clear Cell Renal Carcinoma	1
Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)	1
Advanced Hepatocellular Carcinoma (HCC)	1
ORR,OS,PFS	1
HIV	1
AIDS	1
Refractory Opportunistic Infection	1
NKTCL	1
Local Advanced Rectal Cancer	1
PCSK9 Inhibitor	1
RCT	1
Resectable Oral and Oropharyngeal Squamous Cell Carcinoma	1
Colorectal Cancer Stage IV	1
Advanced Non-Small Cell Lung Cancer	1
Pathological Complete Response	1
Biliary Tract Cancers (BTC)	1
Gastric Cancer or Gastroesophageal Junction Adenocarcinoma	1
Unresectable/Metastatic Gastric Cancer	1
Pancreatic Cancer, Stage IB	1
Pancreatic Cancer, Stage IIA	1
Pancreatic Cancer, Stage IIB	1
Pancreatic Cancer Stage III	1
Advanced HBV-Related Hepatocellular Carcinoma	1
Primary Central Nervous System Hodgkin Lymphoma	1
Sebaceous Gland Carcinoma	1
Metastatic Gastric Cancer	1
Unresectable Gastric Carcinoma	1
Radiotherapy, Adjuvant	1
TACE	1
Neuroendocrine Neoplasm	1
Advanced / Metastatic Solid Tumor	1
Non-small Cell Lung Cancer Stage III	1
Neoplasms	1
Digestive System Diseases	1
Primary Central Nervous System Lymphoma	1
Locally Advanced Gastric Cancer	1
Gastroesophageal Junction Adenocarcinoma (Siewert II-III)	1
Her-2 Negative Breast Cancer	1
HRR Gene Mutation	1
Fertility Preservation	1
Hepatocellulcar Carcinoma	1
Esophageal Neoplasm	1
Sarcomatoid Carcinoma of Lung	1
Unresectable Gallbladder Cancer	1
Metastatic Pancreatic Carcinoma	1
Endometrioid Endometrial Cancer	1
Salivary Gland Carcinoma	1
Precision Therapy	1
Radical Surgery	1
Breast Cancer Triple Negative Breast Cancer	1
Nasopharyngeal Cancer	1
PD-1 Therapy	1
Liver Diseases	1
T-lymphoblastic Lymphoma	1
Second-line Therapy	1
IMMUNOTHERAPY	1
Resectable Lung Non-Small Cell Carcinoma	1
Biomarkers / Blood	1
Neoadjvant Therapy	1
Anti-PD-1	1
Anti-VEGFR	1
Potentially Resectable Hepatocellular Carcinoma	1
Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma	1
Preoperative	1
Endometrial Carcinoma	1
TP53 Mutation	1
Recurrent or Metastatic	1
Unresectable Hepatocellular Carcinoma	1
Acute Myeloid Leukemia	1
Rectal Cancer Patients	1
Breast Neoplasm	1
Breast Tumors	1
Triple-Negative Breast Cancer (TNBC)	1
Immunochemotherapy	1
Breast Cancer Stage IV	1
Triple -Negative Breast Cancer	1
Germline BRCA-mutated HER2-negative Breast Cancer	1
Locally Advanced Head and Neck Cancer	1
Esophageal Diseases	1
PDAC - Pancreatic Ductal Adenocarcinoma	1
PD-L1 Negative	1
RWS	1
PD-1 Immunotherapy	1
Resectable Esophageal Squamous Cell Carcinoma	1
Peripheral T-cell Lymphoma	1
Locally Advanced Gastric Adenocarcinoma	1
Lung Metastasis	1
Low Rectal Cancer	1

By country register

Register	Trials	Recruiting
Clinical trials in China	555	353
Clinical trials in USA	23	14
Clinical trials in UK	5	3
Clinical trials in Ireland	1	0
Clinical trials in India	1	0

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about Tislelizumab trials

How many clinical trials are testing Tislelizumab?

566 current trials in our China, USA, UK, Ireland and India registers name Tislelizumab (also registered as Anti-PD-1 monoclonal antibody) as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.

Are Tislelizumab trials recruiting patients?

Yes. 360 of the 566 trials are recruiting: 353 with sites in China, 14 with sites in USA and 3 with sites in UK. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Tislelizumab clinical trials?

Sun Yat-sen University (58), Fudan University (46), Tianjin Medical University Cancer Institute and Hospital (20) and Cancer Institute and Hospital, Chinese Academy of Medical Sciences (16), among 202 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Is Tislelizumab licensed in Ireland?

Yes. The HPRA medicines list includes 1 single-substance product containing Tislelizumab, for example Tevimbra 100 mg concentrate for solution for infusion (BeiGene Ireland Limited). A licence does not mean a product is currently marketed or reimbursed; see each product's record.

Is there a Tislelizumab shortage?

Not in the lists we track: Tislelizumab has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Tislelizumab works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Tislelizumab works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Tislelizumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Tislelizumab clinical trials